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A B S T R A C T
Background
Acute otitis media (AOM) is one of the most common childhood infectious diseases and a significant reason for antibiotic prescriptions
in children worldwide. Pain from middle ear infection and pressure behind the eardrum is the key symptom of AOM. Ear pain
is central to children’s and parents’ experience of the illness. Because antibiotics provide only marginal benefits, analgesic treatment
including paracetamol (acetaminophen) and non-steroidal anti-inflammatory drugs (NSAIDs) is regarded as the cornerstone of AOM
management in children.
Objectives
Our primary objective was to assess the effectiveness of paracetamol (acetaminophen) or NSAIDs, alone or combined, compared with
placebo or no treatment in relieving pain in children with AOM. Our secondary objective was to assess the effectiveness of NSAIDs
compared with paracetamol in children with AOM.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL), Issue 7, July 2016; MEDLINE (Ovid, from 1946 to
August 2016), Embase (from 1947 to August 2016), CINAHL (from 1981 to August 2016), LILACS (from 1982 to August 2016) and
Web of Science (from 1955 to August 2016) for published trials. We screened reference lists of included studies and relevant systematic
reviews for additional trials. We searched WHO ICTRP, ClinicalTrials.gov, and the Netherlands Trial Registry (NTR) for completed
and ongoing trials (search date 19 August 2016).
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Selection criteria
We included randomised controlled trials (RCTs) comparing the effectiveness of paracetamol or NSAIDs, alone or combined, for pain
relief in children with AOM. We also included trials of paracetamol or NSAIDs, alone or combined, for children with fever or upper
respiratory tract infections (URTIs) if we were able to extract subgroup data on pain relief in children with AOM either directly or after
obtaining additional data from study authors.
Data collection and analysis
Two review authors independently assessed methodological quality of the included trials and extracted data. We used the GRADE
approach to rate the overall quality of evidence for each outcome of interest.
Main results
We included three RCTs (327 children) which were assessed at low to moderate risk of bias.
One RCT included 219 children with AOM, and used a three-arm, parallel group, double-blind design to compare paracetamol versus
ibuprofen versus placebo. All children also received antibiotics and those with fever > 39 °C could have received paracetamol (30 mg
to 60 mg) additionally to the studied treatments.
Another RCT involved 156 febrile children (26 of whom had AOM). The study design was a three-arm, parallel group, double-blind
design and compared paracetamol versus ibuprofen versus ibuprofen plus paracetamol.
The third RCT included 889 children with respiratory tract infections (82 of whom had AOM). This study applied a 3 x 2 x 2 factorial,
open-label design and compared paracetamol versus ibuprofen versus ibuprofen plus paracetamol. Study participants were randomised
to one of the three treatment groups as well as two dosing groups (regular versus as required) and two steam inhalation groups (steam
versus no steam).
Authors of twoRCTs provided crude subgroup data on childrenwith AOM.We used data from the remaining trial to inform comparison
of paracetamol versus placebo (148 children) and ibuprofen versus placebo (146 children) assessments. Data from all included RCTs
informed comparison of ibuprofen versus paracetamol (183 children); data from the two RCTs informed comparison of ibuprofen plus
paracetamol versus paracetamol alone (71 children).
We found evidence, albeit of low quality, that both paracetamol and ibuprofen as monotherapies were more effective than placebo in
relieving pain at 48 hours (paracetamol versus placebo: proportion of children with pain 10% versus 25%, RR 0.38, 95% CI 0.17 to
0.85; number needed to treat to benefit (NNTB) 7; ibuprofen versus placebo: proportion of children with pain 7% versus 25%, RR
0.28, 95% CI 0.11 to 0.70; NNTB 6). Very low quality evidence suggested that adverse events did not significantly differ between
children treated with either paracetamol, ibuprofen or placebo.
We found insufficient evidence of a difference between ibuprofen and paracetamol in relieving ear pain at 24 hours (2 RCTs, 39
children; RR 0.83, 95% CI 0.59 to 1.18; very low quality evidence), 48 to 72 hours (3 RCTs, 183 children; RR 0.91, 95% CI 0.54 to
1.54; low quality evidence) and four to seven days (2 RCTs, 38 children; RR 0.74, 95% CI 0.17 to 3.23; very low quality evidence).
Data on the effectiveness of ibuprofen plus paracetamol versus paracetamol alone came from two RCTs that provided crude subgroup
data for 71 children with AOM. The small sample provided imprecise effect estimates and we were consequently unable to draw any
firm conclusions (very low quality evidence).
Authors’ conclusions
Despite explicit guideline recommendations on its use, current evidence on the effectiveness of paracetamol or NSAIDs, alone or
combined, in relieving pain in children with AOM is limited. Low quality evidence indicates that both paracetamol and ibuprofen as
monotherapies are more effective than placebo in relieving short-term ear pain in children with AOM. There is insufficient evidence of a
difference between ibuprofen and paracetamol in relieving short-term ear pain in children with AOM, whereas data on the effectiveness
of ibuprofen plus paracetamol versus paracetamol alone were insufficient to draw any firm conclusions. Further research is needed to
provide insights into the role of ibuprofen as adjunct to paracetamol, and other analgesics such as anaesthetic eardrops, for children
with AOM.
P L A I N L A N G U A G E S U M M A R Y
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Pain relievers for children with acute middle ear infection
Review question
We wanted to find out if pain relievers are effective for relieving pain in children with acute middle ear infection (acute otitis media
(AOM)) and which medications, alone or together, provide the most effective pain relief.
Background
Acute middle ear infection or AOM is one of the most common childhood infections. Ear pain due to middle ear infection and pressure
building up behind the eardrum is the key symptom of AOM and central to children’s and parents’ experience of the illness. Because
antibiotics provide only marginal benefits, pain relievers such as paracetamol (acetaminophen) and non-steroidal anti-inflammatory
drugs (NSAIDs) are considered the cornerstone of AOM management in children.
Search date
Our evidence is current to 19 August 2016.
Study characteristics
We included data from three trials of low to moderate risk of bias of 327 children with AOM. One trial (219 children) compared
paracetamol versus ibuprofen versus a dummy drug in children with AOM. In this trial, all children also received antibiotic treatment
and those with fever > 39 °Cmay have received paracetamol in addition to the studied treatments. Two other trials compared the effects
of paracetamol versus ibuprofen versus ibuprofen plus paracetamol in children with fever and patients with respiratory tract infections,
respectively. The authors of these two trials provided crude subgroup data on children with AOM (26 and 82 children, respectively).
Study funding sources
In one trial, paracetamol, ibuprofen and a dummy drug were supplied by a pharmaceutical company (Ethypharm). No further details
were provided about the role of this company in the design, conduct, analysis, or reporting of the trial. The other two trials were funded
by governmental (non-commercial) grants. In one trial the drugs were purchased from and provided by two companies (Pfizer and
DHP Investigational Medicinal Products) which had no role in the design, conduct, analysis, or reporting of the trial.
Key results
Very limited information was available to assess how useful painkillers are for relieving children’s pain due to AOM.We found that both
paracetamol and ibuprofen when used alone were more effective than a dummy drug in relieving ear pain at 48 hours (25% of children
receiving a dummy drug had residual pain at 48 hours versus 10% in the paracetamol group and 7% in the ibuprofen group). The
adverse events reported in the trials did not significantly differ between children treated with either paracetamol, ibuprofen or dummy
drug, but this finding should be interpreted cautiously, given there were few participants, and infrequent occurrence of adverse events.
We found insufficient evidence of a difference between paracetamol and ibuprofen in relieving short-term (at 24 hours, 48 to 72 hours
and 4 to 7 days) ear pain in children with AOM.We could not draw any firm conclusions on the effects of ibuprofen plus paracetamol
versus paracetamol alone in relieving ear pain in children with AOM mainly because of the very limited number of participants (very
small sample size).
Quality of evidence
Evidence quality for ear pain relief at 48 hours for the comparisons paracetamol versus a dummy drug and ibuprofen versus a dummy
drug was judged low (study limitations and questions about the applicability of evidence affected our confidence in the results); the
quality of evidence for adverse events was judged very low (study limitations, small sample size and infrequent occurrence of adverse
events affected our confidence in the results).
Evidence quality for ear pain relief at 48 to 72 hours for the comparison ibuprofen versus paracetamol was judged low (study limitations
and questions about the applicability of evidence affected our confidence in the results); the quality of evidence for ear pain relief at 24
hours and four to seven days was judged very low (study limitations and very small sample size affected our confidence in the results).
Evidence quality for all outcomes in the trials comparing ibuprofen plus paracetamol versus paracetamol alone was very low (study
limitations and very small sample size affected our confidence in the results).
3Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in
children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Paracetamol versus placebo for acute otitis media in children
Patients: children with acute ot it is media
Setting: outpat ients in four centres
Intervention: paracetamol
Control: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with paracetamol
Pain at various time
points
24 hours no data available n/ a n/ a n/ a
48 to 72 hours (48 hours) Study populat ion RR 0.38
(0.17 to 0.85)
148
(1 RCT)
⊕⊕©©
low¹
NNTB based on the
study populat ion risk
was 1/ (253 to 96)* 1000
= 7
253 per 1000 96 per 1000
(43 to 215)
4 to 7 days no data available
Adverse events Study populat ion RR 1.03
(0.21 to 4.93)
148
(1 RCT)
⊕©©©
very low²
40 per 1000 41 per 1000
(8 to 197)
M ean time to resolu-
tion of pain
no data available n/ a n/ a n/ a
M ean pain score at var-
ious time points
no data available n/ a n/ a n/ a
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Fever at various time
points
24 hours no data available n/ a n/ a n/ a
48 to 72 hours (48 hours) Study populat ion RR 1.03
(0.07 to 16.12)
148
(1 RCT)
⊕©©©
very low³
13 per 1000 14 per 1000
(1 to 215)
4 to 7 days no data available n/ a n/ a n/ a
Re-consultations no data available n/ a n/ a n/ a
Delayed antibiotic pre-
scriptions
no data available n/ a n/ a n/ a
* The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; NNTB: number needed to treat to benef it ; RR: Risk rat io; RCT: randomised controlled trial;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
¹ We downgraded the evidence f rom high to low quality due to study lim itat ions and quest ions about the applicability of
evidence.
² We downgraded the evidence f rom high to very low quality due to study lim itat ions and imprecise ef fect est imate (small
sample size and inf requent occurrence of the outcome).
³ We downgraded the evidence f rom high to very low quality due to study lim itat ions, imprecise ef fect est imate (inf requent
occurrence of the outcome) and quest ions about the applicability of evidence.
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B A C K G R O U N D
Description of the condition
AOM is one of the most common childhood infectious diseases,
with an estimated incidence of approximately 300 physician-di-
agnosed AOM episodes per 1000 person-years in children aged
up to two years (Liese 2014). By three years of age, over 80%
of all children have experienced at least one AOM episode (Teele
1989). Moreover, AOM is an important cause of antibiotic pre-
scriptions in children (Ashworth 2005; Grijalva 2009). Although
severe complications of AOM, such as acute mastoiditis, menin-
gitis and intracranial abscess, are rare in high-income countries,
AOM significantly impairs quality of life for children and their
parents and carers. AOM is associated with substantial healthcare
resource use and lost work days for parents and carers (Greenberg
2003).
AOM is defined by the presence of middle ear effusion together
with acute onset of signs and symptoms of middle ear inflamma-
tion (Bluestone 2007; Lieberthal 2013). Cardinal signs of AOM
are bulging of the eardrum or new onset of ear discharge not due to
acute otitis externa; typical AOM symptoms include ear pain and
general symptoms of illness such as fever, irritability and problems
feeding and sleeping (Lieberthal 2013). Ear pain due to infection
of the middle ear and pressure behind the eardrum is a major
symptom of AOM (Lieberthal 2013). Pain is central to children’s
and parents’ experience of the illness (Barber 2014; Schechter
2003). Antibiotics provide only marginal benefits (Rovers 2006;
Venekamp 2015), and analgesic treatment, including paracetamol
(acetaminophen) and NSAIDs, is regarded as the cornerstone of
AOM management in children (Lieberthal 2013).
Description of the intervention
The exact mechanism of paracetamol action is not fully under-
stood, but has been assumed to act as a selective inhibitor of COX-
1 and COX-2 in the central nervous system (Bruno 2014). Un-
like NSAIDs, paracetamol does not prevent prostaglandin syn-
thesis by competitive binding to the COX enzyme, but modu-
lates the COX pathway through its ability to reduce COX activity
(Bruno 2014). Although paracetamol might have some peripheral
effects, its main action appears to be located centrally by inhibit-
ing prostaglandin synthesis in the brain (Marzuillo 2014). Due
to its minor peripheral effects, paracetamol lacks significant anti-
inflammatory activity (van den Anker 2013). When administered
as an oral suspension, the peak plasma concentration of paraceta-
mol is reached in around 30 minutes; for oral tablets and sup-
positories this is approximately 30 to 45 minutes and two to four
hours respectively (Marzuillo 2014). The recommended dose of
paracetamol for children is 10 to 15 mg/kg per dose, every four to
six hours orally (van den Anker 2013).
In contrast to paracetamol, NSAIDs have both central and pe-
ripheral effects and can be divided in traditional and selective
COX-2 inhibitors (Bruno 2014). COX-2 inhibition leads to re-
duced release of pyrogenic molecules in the inflamed cells (mainly
prostaglandin E2) causing the anti-inflammatory and analgesic
effects of NSAIDs (Bruno 2014; Rainsford 2009), while COX-
1 inhibition is mainly responsible for gastrointestinal adverse ef-
fects (Bruno 2014). Gastrointestinal adverse effects such as peptic
ulcers or bleeding are caused by a dual effect of NSAIDs on the
gastrointestinal tract; the prostaglandin biosynthesis and main-
tenance of gastric mucosal integrity (Bruno 2014). Ibuprofen, a
non-selective COX inhibitor, is the most commonly used NSAID
in children, with a recommended dose of 5 to 10 mg/kg per dose
every six to eight hours orally, to a maximum dose of 500 mg
per day (van den Anker 2013). The relatively low incidence of
serious gastrointestinal adverse effects associated with ibuprofen,
as compared with other NSAIDs, is thought to be the result of
its relatively short half-life (Rainsford 2009). However, ibuprofen,
like other NSAIDs, is associated with rare but serious adverse drug
reactions of the skin (Stevens-Johnson syndrome), renal (papillary
necrosis) and cardiovascular systems (Rainsford 2009). Further-
more, ibuprofen has been associated with an increased risk of in-
ducing bronchospasm in children with asthma (Rainsford 2009).
However, a recent study found no association between paraceta-
mol or ibuprofen and early childhood asthma when adjusted for
potential confounding (Sordillo 2015). Compared with paraceta-
mol, ibuprofen has a longer duration of action, and as such, has
the advantage of less frequent dosing (every 6 to 8 hours versus
every 4 hours for paracetamol) (van den Anker 2013).
How the intervention might work
Because pain is a major symptom of AOM in children, current
guidance explicitly recommends analgesic treatment, irrespective
of antibiotics use (Lieberthal 2013). In daily practice, paraceta-
mol and NSAIDs (ibuprofen) are widely used for relieving pain
and fever in children. Paracetamol is generally considered to be
well tolerated and safe with only few adverse effects, such as rash
and other allergic reactions, when used at therapeutic dosages
(Marzuillo 2014; Southey 2009). However, paracetamol has the
potential for hepatotoxicity following overdose (Marzuillo 2014).
In general, the safety profile of ibuprofen is considered to be com-
parable with paracetamol when both drugs are used at the rec-
ommended doses and in the absence of specific contraindications
(children with gastrointestinal bleeding or ulcers, congenital heart
disease, severe kidney and liver disease, concurrent use of anticoag-
ulant and steroid drugs, and in children aged less than six months)
(Southey 2009; van den Anker 2013).
Why it is important to do this review
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Whilst the effectiveness of analgesic eardrops in children with
AOMhas been reviewed (Foxlee 2006), this has not been done for
paracetamol or NSAIDs, alone or combined. Previous Cochrane
reviews on paracetamol or NSAIDs (or both) focused either on
children with fever due to infectious diseases (Meremikwu 2005;
Wong 2013), or included both children and adults with the com-
mon cold (Kim2013). As such, these reviews did not includeRCTs
on paracetamol or NSAIDs (or both) for relieving symptoms in
childhood AOM. Since AOM is a specific clinical entity with a
high incidence and substantial societal impact, a comprehensive
literature search and systematic review was warranted to assess 1)
the effectiveness of paracetamol or NSAIDs, alone or combined,
compared with placebo or no treatment in relieving pain in chil-
dren with AOM and 2) whether the effects of NSAIDs and parac-
etamol in terms of relieving pain differ in children with AOM.
O B J E C T I V E S
Our primary objective was to assess the effectiveness of paraceta-
mol (acetaminophen) or NSAIDs, alone or combined, compared
with placebo or no treatment in relieving pain in children with
AOM. Our secondary objective was to assess the effectiveness of
NSAIDs as compared with paracetamol in children with AOM.
M E T H O D S
Criteria for considering studies for this review
Types of studies
RCTs assessing the effectiveness of paracetamol or NSAIDs, alone
or combined, in relieving pain in children with AOM.
We also included trials of paracetamol or NSAIDs, alone or com-
bined, for children with fever or URTIs if we could extract sub-
group data on pain relief (including discomfort, distress and/or
irritability) in children with AOM either directly or upon request
by the original trial authors.
We intended to include trials reporting concurrent therapy (e.g.
co-treatment with oral or topical antibiotics) if we could make di-
rect comparison between the intervention and control group (e.g.
paracetamol with concurrent antibiotic therapy versus placebo
with concurrent antibiotic therapy) and if participants in each arm
were not treated differently.We defined ’not treated differently’ as
a maximum of 10% difference in the proportion of children who
received the concurrent therapy in the intervention and control
groups.
Types of participants
We included children aged from six months to 16 years with AOM
irrespective of the diagnostic criteria used. We excluded studies
on children with grommets (ventilation tubes or tympanostomy
tubes) in place and those in which children were hospitalised. (See
Differences between protocol and review).
Types of interventions
We included trials of paracetamol andNSAIDs administered orally
or rectally. We excluded trials of paracetamol or NSAIDS admin-
istered parenterally (intravenous administration).
Types of outcome measures
We analysed primary and secondary outcomes, but they were not
used as a basis for including or excluding studies.
Primary outcomes
1. Proportion of children with pain (yes/no) as rated by
parents or carers or children themselves at various time points
(24 hours, 48 to 72 hours, 4 to 7 days);
2. Adverse events likely to be related to the use of paracetamol
or NSAIDs (or both), such as kidney failure or dysfunction, liver
failure or dysfunction, gastrointestinal complaints or bleeding,
and hypersensitivity reactions such as erythema, urticaria (hives,
skin itching) or anaphylactic shock.
Secondary outcomes
1. Proportion of children with at most mild pain (defined as
pain less than or equal to 3/10 on a 0 to 10 numerical pain rating
scale or less than or equal to 30 mm on a 0 to 100 mm visual
analogue scale) as rated by parents, carers or patients at various
time points (24 hours, 48 to 72 hours, 4 to 7 days);
2. Mean time to resolution of pain;
3. Mean pain score at various time points (24 hours; 48 to 72
hours; 4 to 7 days) using validated pain scores;
4. Disease-specific quality of life as measured by a validated
instrument (e.g. AOM Severity of Symptoms Scale (SOS) survey,
OM-6 questionnaire);
5. Mean time to resolution of fever;
6. Proportion of children with fever at various time points (24
hours; 48 to 72 hours; 4 to 7 days);
7. Proportion of children with re-consultations at various time
points;
8. Proportion of children with (delayed) antibiotic
prescriptions at various time points;
9. Total days lost from nursery or school for children because
of AOM;
10. Total days lost from work or education for parents and
carers because of their child’s AOM; and
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11. Serious complications related to AOM such as acute
mastoiditis and meningitis.
Search methods for identification of studies
The Cochrane Acute Respiratory Infections (ARI) Information
Specialist conducted systematic searches for RCTs and controlled
clinical trials. There were no language, publication year or publi-
cation status restrictions. We searched up to 19 August 2016.
Electronic searches
We searched the Cochrane Central Register of Controlled Tri-
als (CENTRAL), Issue 7, July 2016, which contains the Acute
Respiratory Infections Group’s Specialised Register (Appendix 1),
MEDLINE (1946 to August 2016) (Appendix 2), Embase (1947
to August 2016) (Appendix 3), CINAHL (1981 to August 2016)
(Appendix 4), LILACS (1982 to August 2016) (Appendix 5) and
Web of Science (1955 to August 2016) (Appendix 6). We used
the Cochrane Highly Sensitive Search Strategy for identifying ran-
domised trials in MEDLINE: sensitivity- and precision-maximis-
ing version (2008 revision); Ovid format and adapted the search
strategy for Embase, CINAHL, LILACS and Web of Science
searches.
Searching other resources
We searched the World Health Organization (WHO) Interna-
tional Clinical Trials Registry Platform (ICTRP), ClinicalTri-
als.gov, and the Netherlands Trial Registry (NTR) for completed
and ongoing trials. We scanned the reference lists of identified
publications for additional trials and contacted trial authors if
necessary. We also searched MEDLINE, TRIP database and the
Cochrane Library to retrieve any published systematic reviews rel-
evant to this review and scanned their citations for additional tri-
als. Furthermore, we searched the extended abstracts published in
the Proceedings from the International Symposia on Recent Ad-
vances in Otitis Media (grey literature) for any additional trials.
Data collection and analysis
Selection of studies
Two review authors (AS, RPV) independently screened titles and
abstracts and scanned citations of potentially relevant reviews re-
trieved from database searches. The same review authors indepen-
dently reviewed the full text of potentially relevant studies for in-
clusion. We resolved any disagreements by discussion. See Figure
1.
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Figure 1. Study flow diagram
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Data extraction and management
Two review authors (AS, RPV) independently extracted data from
the included studies using standardised data extraction forms. We
extracted the following information from each trial:
1. Study characteristics: setting, design, method of data-
analysis.
2. Participants: study population, number of participants in
each group, patient characteristics including age, gender,
ethnicity.
3. Interventions: type of intervention used including timing
and dosage and route of administration.
4. Outcomes: primary and secondary outcomes recorded,
time points.
We resolved any disagreements by discussion.
Assessment of risk of bias in included studies
Two review authors (AS, RPV) independently assessed the
methodological quality of the included trials. We resolved any dis-
agreements by discussion. We assessed risk of bias using the ’Risk
of bias’ tool as described in Chapter 8 of theCochrane Handbook
for Systematic Reviews of Interventions (Higgins 2011). We judged
the following domains as high, low or unclear risk of bias:
1. sequence generation (selection bias).
2. Allocation concealment (selection bias).
3. Blinding of participants and personnel (performance bias).
4. Blinding of outcome assessment (detection bias).
5. Incomplete outcome data (attrition bias).
6. Selective outcome reporting (reporting bias).
7. Other sources of bias.
The results of the ’Risk of bias’ assessment are presented in Figure
2 and Figure 3.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies
Measures of treatment effect
We expressed dichotomous outcomes as risk ratios (RRs) with ac-
companying 95% confidence intervals (CIs) and calculated the
number needed to treat to benefit (NNTB). We expressed con-
tinuous outcome variables either as mean differences (MDs) if re-
ported on the same scale or standardised mean differences (SMD)
if different continuous scales were used, with accompanying 95%
CIs.
Unit of analysis issues
We did not identify any studies with non-standard designs, such
as cross-over trials or cluster-randomised trials.
Dealing with missing data
In cases of missing data, we contacted corresponding authors of
the included trials to provide additional information. In primary
analyses, we analysed available data according to the intention-to-
treat (ITT) principle, that is, we analysed all participants in the
group to which they were originally allocated. For dichotomous
outcomes, we proposed to assess the impact of incomplete data
reporting by performing scenario analyses (best and worst-case
scenarios). For mean ear pain score at various time points, we
proposed to assess the impact of missing outcome data by using
the baseline observation carried forward approach (Moore 2012).
Assessment of heterogeneity
We considered both clinical and statistical heterogeneity. We as-
sessed the level of clinical diversity among trials by reviewing in-
cluded studies for potential differences in study populations, inter-
ventions, and outcomes measured. We assessed statistical hetero-
geneity for each outcome by visual inspection of forest plots and
using the Chi² test, with a significance level set at P < 0.10, and
the I² statistic (Higgins 2003); I² values of 50% or more suggest
substantial heterogeneity (Higgins 2011).
Where there was substantial statistical heterogeneity, we proposed
to carry out pre-specified subgroup analyses and sensitivity analyses
based on the risk of bias (see Subgroup analysis and investigation
of heterogeneity; Sensitivity analysis). If none of these analyses
completely resolved statistical heterogeneity, we employed a ran-
dom-effects (Der Simonian and Laird) model to provide a more
conservative effect estimate.
Assessment of reporting biases
We searched the Internet and ClinicalTrials.gov (http://
clinicaltrials.gov/) for relevant study protocols to determine if all
outcomes listed in study protocols had been published and if all
outcomes reportedwere pre-defined.We intended to assess report-
ing biases by using funnel plots if there were sufficient included
trials.
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Data synthesis
We primarily performed available case analyses, so using data for
every participant for whom the outcome was obtained, according
to the ITT principle.
For both primary and secondary dichotomous outcomesmeasured
at various time points, we primarily performed a meta-analysis
using a wide window of one to seven days. In secondary anal-
yses, we used the specific time point reported in most studies.
We performed statistical analyses using Review Manager software
(RevMan 2014)
For the comparison of NSAIDs plus background therapy (parac-
etamol) versus background therapy only, we performed a meta-
analysis of studies comparing NSAIDs plus background therapy
versus background therapy only.
For dichotomous data, we calculated RR with 95% CIs using
the Mantel-Haenszel method with a fixed-effect model if appro-
priate or the random-effects (Der Simonian and Laird) model
where unexplained heterogeneity was found (see Assessment of
heterogeneity). We also calculated the NNTB or number needed
to harm (NNTH) based on the average risks of the control groups
in the included studies (study population) (Higgins 2011).
GRADE and ’Summary of findings’ tables
We used the GRADE (Atkins 2004) approach to rate the overall
quality of evidence for any of the outcomes of interest reported
in the included trials, and drew conclusions about the quality of
evidence. There are four possible ratings: high, moderate, low and
very low. The GRADE approach rates evidence from RCTs which
do not have serious limitations as high quality. However, several
factors can lead to the downgrading of the evidence. The degree of
downgrading is determined by the seriousness of the these factors:
study limitations, consistency of effect, imprecision, indirectness
and publication bias to assess the quality of a body of evidence as
it relates to the studies which contribute data to the meta-anal-
yses for the prespecified outcomes. We used methods and rec-
ommendations described in Section 8.5 and Chapter 12 of the
CochraneHandbook for Systematic Reviews of Interventions (Higgins
2011) used GRADEproGDT software (GRADEproGDT 2015).
We justified all decisions to downgrade the quality of studies using
footnotes, and we made comments to aid the reader’s understand-
ing of the review where necessary.
We provided summary of findings tables for themain comparisons
of interest paracetamol versus placebo, NSAIDs versus placebo
and NSAIDs versus paracetamol including what we felt the seven
most important outcomes:
1. Proportion of children with pain (yes/no) at various time
points (24 hours, 48 to 72 hours, 4 to 7 days);
2. Adverse events;
3. Mean time to resolution of pain;
4. Mean pain score at various time points (24 hours; 48 to 72
hours; 4 to 7 days) using validated pain scores;
5. Proportion of children with fever at various time points (24
hours; 48 to 72 hours; 4 to 7 days);
6. Proportion of children with re-consultations at various time
points; and
7. Proportion of children with (delayed) antibiotic
prescriptions at various time points;
Subgroup analysis and investigation of heterogeneity
We planned to perform subgroup analysis for the following cate-
gories if sufficient data were available:
1. Age (up to 2 years versus 2 years and above).
2. Route of administration of analgesics (oral versus rectal).
3. Concurrent therapy (concurrent antibiotic therapy versus
no concurrent antibiotic therapy); and
4. Definition of AOM (AOM diagnosis based solely on
symptoms versus AOM diagnosis based on symptoms and
bulging of the eardrum or new onset of ear discharge not due to
acute otitis externa).
Sensitivity analysis
To assess the robustness of reviewfindings, we intended to perform
a sensitivity analysis in which trials with high risk of bias were
excluded. High risk of bias was defined as high risk of concealment
of allocation bias or attrition bias.
For dichotomous outcomes, we intended to assess the impact of in-
complete data reporting by performing scenario analyses (best and
worst-case scenarios) and for mean ear pain score at various time
points using the baseline observation carried forward approach in
case of incomplete outcome reporting (see Dealing with missing
data).
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of
excluded studies; Characteristics of studies awaiting classification;
Characteristics of ongoing studies.
Results of the search
We retrieved a total of 1869 records from our electronic database
searches. Following removal of duplicates we assessed 1573 unique
articles. After screening titles and abstracts, we identified 24 poten-
tially eligible articles. After reviewing full text reports, we excluded
22 articles: three were non-randomised studies (Campos 1992;
Schuetz 2014; Siegel 2003), five included only adults (Azuma
2010; Eccles 2006; Motoichi 1997; Nouri 1984; Ryan 1987),
two did not include children with AOM (Caretti 1986; Gonzales
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1989), one included hospitalised children (Polidori 1993) and 11
did not include relevant interventions and comparators (Cappella
1993; Dasgupta 2002; Fort 2000; Kim CK 2013; Metta 2000;
Milvio 1984; Passali 2001; Siquet 1983; Stipon 1983; Weippl
1985; Yoon 2008). (See also: Excluded studies). We therefore in-
cluded two studies from our electronic database searches in this
review (Bertin 1996; Little 2013) (Figure 1). Little 2013 did not
report subgroup data for children with AOM in the trial publi-
cation; data were provided by the first author of this trial (Paul
Little).
After reviewing the reference lists of relevant systematic reviews, we
identified three additional potentially relevant articles (Hay 2009;
McIntyre 1996; Sarrell 2006). We excluded one study because it
includedhospitalised children (McIntyre 1996). Since neitherHay
2009 nor Sarrell 2006 reported subgroup data for children with
AOM, we contacted the lead trial authors. We did not succeed in
obtaining additional data in relation to Sarrell 2006, but relevant
datawere provided by the first author (AlastairHay) forHay 2009.
Adding this one to the two studies retrieved from our electronic
database searches led to a total of three included studies (Bertin
1996; Hay 2009; Little 2013) (Figure 1).
We did neither identify additional relevant trials nor any com-
pleted studies after reviewing trials registries WHO ICTRP, Clin-
icalTrials.gov, and the NTR for completed and ongoing trials
(search date 19 August 2016), but we did find one ongoing trial
(PIM-POM study 2014; see Characteristics of ongoing studies).
Included studies
We included three studies that presented data for a total of 327 chil-
dren with AOM (Bertin 1996; Hay 2009; Little 2013). Methods,
participants, interventions and outcomes of the included studies
are described in Characteristics of included studies.
Design
Two trials applied three arm, parallel group, double-blind design
(Bertin 1996; Hay 2009); one was a 3 x 2 x 2 factorial, open-label,
design (Little 2013).
Participants and settings
In Bertin 1996, all 219 children aged from one year to seven years
were diagnosed with AOM. Hay 2009 included 156 febrile chil-
dren aged from six months to six years of whom 26 were diagnosed
with AOM; Little 2013 included 889 children aged three years
and over with respiratory tract infections of whom 82 had AOM.
We therefore included data from 327 children.
AOM diagnosis was based on the aspect of the eardrum in Bertin
1996, whereas AOM was diagnosed either by the general practi-
tioner (GP) or research nurse without further specification of di-
agnostic criteria in Hay 2009 and Little 2013.
Little 2013 was performed in a primary care setting; Hay 2009 in
the community, primary and secondary care settings; the setting
was unclear in Bertin 1996 (all children were seen as outpatients
in 4 centres without further specification).
Interventions and comparators
Bertin 1996 compared paracetamol (10 mg/kg 3 times daily) ver-
sus NSAIDs (ibuprofen 10 mg/kg 3 times daily) versus placebo.
Hay 2009, a three arm, parallel group trial compared paracetamol
(15mg/kg orally,maximumof 4doses in 24 hours) versusNSAIDs
(ibuprofen 10 mg/kg, maximum of 3 doses in 24 hours) versus
NSAID plus paracetamol. Little 2013 applied a 3 x 2 x 2 facto-
rial design and compared paracetamol versus NSAIDs (ibuprofen)
versus NSAIDs (ibuprofen) plus paracetamol. Children in Little
2013 were randomised to both one of the three treatment groups
but also to one of two dosing regimens (regularly or as required)
and one of two steam inhalation therapy groups (steam versus
no steam). Doses of paracetamol and ibuprofen used in this trial
were the maximum recommended by the British National For-
mulary (which varies by age) (https://www.bnf.org/products/bnf-
online/).
Bertin 1996 prescribed concurrent antibiotic therapy (cefaclor 15
mg to 30 mg/kg twice daily for 7 days). Furthermore, children
with fever > 39° C could be given paracetamol (30 mg to 60 mg)
in addition to the studied treatments in Bertin 1996.
Outcomes
Relevant data derived from at least one trial could be extracted for
all outcomes, except for the secondary outcomes days lost from
nursery or school for children because of AOM and days lost from
work or education for parents and carers because of their child’s
AOM.
In Bertin 1996 ear pain was reported as a dichotomous outcome
(yes versus no). Hay 2009 assessed fever-associated discomfort
using a validated comfort scale (no comfort; not quite normal;
some pain/distress; crying/very distressed), whereas Little 2013
assessed ear pain using a validated symptom score (ranging from
0 to 6 with 0 = no problem and 6 = as bad as it could be).
Funding sources
In Bertin 1996, study medications were supplied by a pharma-
ceutical company (Ethypharm); no further details were provided
about the role of this company in the design, conduct, analysis, or
reporting of the trial. The other two trials (Hay 2009; Little 2013)
were funded by governmental (non-commercial) grants. In Hay
2009, study medications were purchased from and provided by
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two companies (Pfizer and DHP Investigational Medicinal Prod-
ucts); these companies had no role in the design, conduct, analysis,
or reporting of the trial.
Excluded studies
We excluded 24 studies:
• three were non-randomised studies (Campos 1992; Schuetz
2014; Siegel 2003);
• five included only adults (Azuma 2010; Eccles 2006;
Motoichi 1997; Nouri 1984; Ryan 1987);
• two did not include children with AOM (Caretti 1986;
Gonzales 1989);
• two included hospitalised children (McIntyre 1996;
Polidori 1993);
• 11 did not include relevant interventions and comparators
(Cappella 1993; Dasgupta 2002; Fort 2000; Kim CK 2013;
Metta 2000; Milvio 1984; Passali 2001; Siquet 1983; Stipon
1983; Weippl 1985; Yoon 2008);
• one did not report crude subgroup data of children with
AOM and we were unsuccessful in obtaining additional data
from the authors (Sarrell 2006).
Risk of bias in included studies
The methodological quality of the included studies was generally
high. Details of the risk of bias assessment of the included trials
are summarised in Figure 2 and Figure 3.
Allocation
Random sequence generation was judged adequate in all three
trials. Concealment of allocation was adequately described in Hay
2009 and Little 2013, but was unclear in Bertin 1996.
Blinding
The risk of bias for blinding of participants, personnel and out-
come assessors (performance and detection bias) was low in Bertin
1996 and Hay 2009 and high in Little 2013.
Incomplete outcome data
Risk of attrition bias was low in Bertin 1996 and Hay 2009 and
unclear in Little 2013.
Selective reporting
Risk of reporting bias was low in Hay 2009 and Little 2013. We
could not retrieve the trial protocol for Bertin 1996 and were
unable determine the risk of selective outcome reporting bias.
Other potential sources of bias
Risk of other potential sources of bias was low in Hay 2009 and
Little 2013 and unclear in Bertin 1996.
Effects of interventions
See: Summary of findings for themain comparisonParacetamol
versus placebo for acute otitis media in children; Summary of
findings 2 NSAIDs versus placebo for acute otitis media in
children; Summary of findings 3NSAIDs versus paracetamol for
acute otitis media in children
Paracetamol versus placebo
Primary outcomes
1. Proportion of children with pain at 48 hours
We included data fromone trial for this outcome (148 randomised
children, 148 (100%) included in analysis) (Bertin 1996). At 48
hours, fewer children in the paracetamol group had pain than
those allocated to placebo (10% versus 25%, RR 0.38, 95% CI
0.17 to 0.85; NNTB 7) (Analysis 1.1; Figure 4).
Figure 4. Forest plot of comparison: 1 Paracetamol versus placebo, outcome: 1.1 Pain at 48 hours
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Quality of evidence
The evidence for this outcome was low quality; we downgraded
it from high to low quality due to study limitations and questions
about the applicability of evidence. All children received concur-
rent antibiotic therapy, and those with fever > 39 °C could be
given paracetamol (30 mg to 60 mg) in addition to the studied
treatments. This may have substantially influenced trial findings.
2. Adverse events likely to be related to the use of
paracetamol
We included data fromone trial for this outcome (148 randomised
children, 148 (100%) included in analysis) (Bertin 1996). Adverse
events were reported infrequently and did not significantly differ
between children treated with paracetamol and those allocated to
placebo (4% versus 4%, RR 1.03, 95% CI 0.21 to 4.93) (Analysis
1.2).
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to low quality due to study limitations and
imprecise effect estimate (small sample size and infrequent occur-
rence of the outcome).
Secondary outcomes
6. Proportion of children with fever at 48 hours
We included data fromone trial for this outcome (148 randomised
children, 148 (100%) included in analysis) (Bertin 1996). At 48
hours, the proportion of children with fever did not significantly
differ between the paracetamol and placebo groups (1% versus
1%, RR 1.03, 95% CI 0.07 to 16.12) (Analysis 1.3).
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations,
imprecise effect estimate (infrequent occurrence of the outcome)
and questions about the applicability of evidence. All children re-
ceived concurrent antibiotic therapy and those with fever > 39 °C
could be given paracetamol (30 mg to 60 mg) in addition to the
studied treatments. This may have substantially influenced trial
findings.
Other pre-specified secondary outcomes
None of the other pre-specified secondary outcomes were reported
for the comparison paracetamol versus placebo.
NSAIDs (ibuprofen) versus placebo
Primary outcomes
1. Proportion of children with pain at 48 hours
We included data fromone trial for this outcome (146 randomised
children, 146 (100%) included in analysis) (Bertin 1996). At 48
hours, fewer children in the ibuprofen group had pain than those
allocated to placebo (7% versus 25%, RR 0.28, 95% CI 0.11 to
0.70; NNTB 6) (Analysis 2.1; Figure 5).
Figure 5. Forest plot of comparison: 2 NSAIDs versus placebo, outcome: 2.1 Pain at 48 hours
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Quality of evidence
The evidence for this outcome was low quality; we downgraded
it from high to low quality due to study limitations and questions
about the applicability of evidence. All children received concur-
rent antibiotic therapy and those with fever > 39 °C could be given
paracetamol (30 mg to 60 mg) in addition to the studied treat-
ments. This may have substantially influenced trial findings.
2. Adverse events likely to be related to the use of NSAIDs
(ibuprofen)
We included data fromone trial for this outcome (146 randomised
children, 146 (100%) included in analysis) (Bertin 1996). Adverse
events were reported infrequently and did not significantly differ
between children treated with ibuprofen and those allocated to
placebo (7% versus 4%, RR 1.76, 95% CI 0.44 to 7.10) (Analysis
2.2).
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (small sample size and infrequent
occurrence of the outcome).
Secondary outcomes
6. Proportion of children with fever at 48 hours
We included data fromone trial for this outcome (146 randomised
children, 146 (100%) included in analysis) (Bertin 1996). At 48
hours, the proportion of children with fever did not significantly
differ between the ibuprofen and placebo groups (1% versus 1%,
RR 1.06, 95% CI 0.07 to 16.57) (Analysis 2.3).
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations,
imprecise effect estimate (infrequent occurrence of the outcome)
and questions about the applicability of evidence. All children re-
ceived concurrent antibiotic therapy and those with fever > 39 °C
could be given paracetamol (30 mg to 60 mg) in addition to the
studied treatments. This may have substantially influenced trial
findings.
Other pre-specified secondary outcomes
None of the other pre-specified secondary outcomes were reported
for the comparison NSAIDs (ibuprofen) versus placebo.
NSAIDs (ibuprofen) versus paracetamol
Primary outcomes
1. Proportion of children with pain at various time points
24 hours
We pooled data from two trials for this outcome (71 randomised
children, 39 (55%) included in analysis) (Hay 2009; Little 2013).
At 24 hours, the proportion of children with pain did not signif-
icantly differ between those treated with ibuprofen and paraceta-
mol (57% versus 78%, RR 0.83, 95% CI 0.59 to 1.18, I² statistic
= 0%, fixed-effect model) (Analysis 3.1). Subgroup and sensitivity
analyses were deemed not to be useful because of the low number
of trials and included children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
48 to 72 hours
We pooled data from three trials for this outcome (215 ran-
domised children, 183 (85%) included in analysis) (Bertin 1996;
Hay 2009; Little 2013). The proportion of children with pain at
48 to 72 hours did not significantly differ between those treated
with ibuprofen and paracetamol (17% versus 18%, RR 0.91, 95%
CI 0.54 to 1.54; I² statistic = 0%, fixed-effect model) (Analysis
3.2; Figure 6). Subgroup and sensitivity analyses were deemed not
useful because of the low number of trials.
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Figure 6. Forest plot of comparison: 3 NSAIDs versus paracetamol, outcome: 3.2 Pain at 48 to 72 hours
Quality of evidence
The evidence for this outcome was low quality; we downgraded
it from high to low quality due to study limitations and questions
about the applicability of evidence. All children in Bertin 1996
received concurrent antibiotic therapy and those with fever > 39
°C could be given paracetamol (30mg to 60mg) in addition to the
studied treatments. This may have substantially influenced trial
findings.
Four to seven days
We pooled data from two trials for this outcome (71 randomised
children, 38 (54%) children included in analysis) (Hay 2009; Little
2013). The proportion of children with pain at four to seven days
did not significantly differ between those treated with ibuprofen
andparacetamol (14%versus 19%,RR0.74, 95%CI0.17 to 3.23;
I² statistic = 36%, fixed-effect model) (Analysis 3.3). Subgroup
and sensitivity analyses were deemed not to be useful because of
the low number of trials and included children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
2. Adverse events likely to be related to the use of
paracetamol or NSAIDs (ibuprofen)
We pooled data from two trials for this outcome (197 randomised
children; 197 (100%) included in analysis) (Bertin 1996; Little
2013). Adverse events were reported infrequently and did not sig-
nificantly differ between children treatedwith ibuprofen and those
treated with paracetamol (5% versus 3%, RR 1.71, 0.43 to 6.90;
I² statistic = n/a, random-effects model) (Analysis 3.4). Subgroup
and sensitivity analyses were deemed not to be useful because of
the low number of trials.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (small sample size and infrequent
occurrence of the outcome).
Secondary outcomes
1. Proportion of children with at most mild pain at various
time points
24 hours
We pooled data from two trials for this outcome (71 randomised
children, 39 (55%) included in analysis) (Hay 2009; Little 2013).
No significant differences were observed between ibuprofen and
paracetamol groups in the proportion of children with mild pain
at 24 hours (18% versus 18%, RR 1.08, 95% CI 0.31 to 3.73; I²
statistic = 0%, fixed-effect model) (Analysis 3.5). Subgroup and
sensitivity analyses were deemed not to be useful because of the
low number of trials and included children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
48 to 72 hours
We pooled data from two trials for this outcome (71 randomised
children, 39 (55%) included in analysis) (Hay 2009; Little 2013).
No significant differences were observed between ibuprofen and
paracetamol groups in the proportion of childrenwithmild pain at
48 to 72 hours (36% versus 29%, RR 1.35, 95% CI 0.62 to 2.91;
I² statistic = 0%, fixed-effect model) (Analysis 3.6). Subgroup and
sensitivity analyses were deemed not to be useful because of the
low number of trials and included children.
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Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
Four to seven days
We pooled data from two trials for this outcome (71 randomised
children, 39 (55%) included in analysis) (Hay 2009; Little 2013).
No significant differences were observed between ibuprofen and
paracetamol groups in the proportion of children with mild pain
at four to seven days (23% versus 29%). Data did not enable
pooling of trial results; the summary statistic relates only to Little
2013 (RR 0.91, 95% CI 0.37 to 2.23) (Analysis 3.7). Subgroup
and sensitivity analyses were deemed not to be useful because of
the low number of trials and included children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
2. Mean time to resolution of pain
None of the included trials reported on this pre-specified sec-
ondary outcome.
3. Mean pain score at various time points
24 hours
We pooled data from two trials for this outcome (71 randomised
children, 39 (55%) included in analysis) (Hay 2009; Little 2013).
No differences were observed in mean pain scores at 24 hours
between children treated with ibuprofen and paracetamol (MD
0.10, 95% CI -0.47 to 0.67; I² statistic = 0%, fixed-effect model)
(Analysis 3.8). Subgroup and sensitivity analyses were deemed not
to be useful because of the low number of trials and included
children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
48 to 72 hours
We pooled data from two trials for this outcome (71 randomised
children, 39 (55%) included in analysis) (Hay 2009; Little 2013).
Nodifferences were observed inmean pain scores at 48 to 72 hours
between children treated with ibuprofen and paracetamol (MD
0.19, 95% CI -0.27 to 0.65; I² statistic = 0%, fixed-effect model)
(Analysis 3.9). Subgroup and sensitivity analyses were deemed not
to be useful because of the low number of trials and included
children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
4 to 7 days
We pooled data from two trials for this outcome (71 randomised
children, 31 (44%) included in analysis) (Hay 2009; Little 2013).
No differences were observed in mean pain scores at four to seven
days between children treated with ibuprofen and paracetamol.
Data did not enable pooling of trial results; the summary statistic
relates only to Little 2013 (MD -0.30, 95% CI -2.38 to 1.78)
(Analysis 3.10). Subgroup and sensitivity analyses were deemed
not to be useful because of the low number of trials and included
children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
4. Disease-specific quality of life as measured by a validated
instrument
None of the included trials reported on this pre-specified sec-
ondary outcome.
5. Mean time to resolution of fever
None of the included trials reported on this pre-specified sec-
ondary outcome.
6. Proportion of children with fever at various time points
24 hours
We pooled data from two trials for this outcome (71 randomised
children, 39 (55%) included in analysis) (Hay 2009; Little 2013).
Nodifferencewas observed in the proportionof childrenwith fever
at 24 hours between those treated with ibuprofen and paracetamol
(18% versus 29%, RR 0.69, 95% CI 0.24 to 2.00; I² statistic =
0%, fixed-effect model) (Analysis 3.11). Subgroup and sensitivity
analyses were deemed not to be useful because of the low number
of trials and included children.
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Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
48 to 72 hours
Wepooled data from three trials for this outcome (215 randomised
children, 182 (85%) included in analysis) (Bertin 1996;Hay 2009;
Little 2013). No difference was observed in the proportion of
children with fever at 48 to 72 hours between those treated with
ibuprofen and paracetamol (4% versus 3%, RR 1.18, 95% CI
0.31 to 4.44; I² statistic = 0%, fixed-effect model) (Analysis 3.12).
Subgroup and sensitivity analyses were deemed not to be useful
because of the low number of trials.
Quality of evidence
The evidence for this outcome was low quality; we downgraded
it from high to low quality due to study limitations and questions
about the applicability of evidence. All children in Bertin 1996
received concurrent antibiotic therapy and those with fever > 39
°C could be given paracetamol (30mg to 60mg) in addition to the
studied treatments. This may have substantially influenced trial
findings.
4 to 7 days
We pooled data from two trials for this outcome (71 randomised
children, 39 (55%) included in analysis) (Hay 2009; Little 2013).
No difference was observed in the proportion of children with
fever at four to seven days between those treated with ibuprofen
and paracetamol (5% versus 0%). Data did not enable pooling
of trial results; the summary statistic relates only to Little 2013
(RR 2.75, 95% CI 0.12 to 60.70) (Analysis 3.13). Subgroup and
sensitivity analyses were deemed not to be useful because of the
low number of trials and included children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
7. Proportion of children with re-consultations
We included data from one trial for this outcome (53 randomised
children, 53 (100%) included in analysis) (Little 2013). No dif-
ference was observed in the proportion of children with re-con-
sultations at day 28 between those treated with ibuprofen and
paracetamol (92% versus 81%, RR 1.13, 95% CI 0.92 to 1.40)
(Analysis 3.14).
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
8. Proportion of children with (delayed) antibiotic
prescriptions
We included data from one trial for this outcome (53 randomised
children, 53 (100%) included in analysis) (Little 2013). No dif-
ference was observed in the proportion of children with delayed
antibiotics between those treated with ibuprofen and paracetamol
(54% versus 41%, RR 1.32, 95%CI 0.74 to 2.35) (Analysis 3.15).
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
9. Total days lost from nursery or school for children
because of AOM
None of the included trials reported on this pre-specified sec-
ondary outcome.
10. Total days lost from work or education for parents and
carers because of their child’s AOM
None of the included trials reported on this pre-specified sec-
ondary outcome.
11. Serious complications
We pooled data from two trials for this outcome (71 randomised
children, 71 (100%) included in analysis) (Hay 2009; Little 2013).
No serious complications related to AOM were reported in either
of the trials. Subgroup and sensitivity analyses were deemed not
to be useful because of the low number of trials and included
children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (small sample size and infrequent
occurrence of the outcome).
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NSAIDs (ibuprofen) and paracetamol versus
paracetamol
Primary outcomes
1. Proportion of children with pain at various time points
24 hours
We pooled data from two trials for this outcome (71 randomised
children, 41 (58%) included in analysis) (Hay 2009; Little 2013).
At 24 hours, the proportion of children with pain did not signif-
icantly differ between those treated with ibuprofen and paraceta-
mol versus paracetamol alone (79% versus 71%, RR 1.07, 95%CI
0.78 to 1.47, I² statistic = 0%, fixed-effect model) (Analysis 4.1).
Subgroup and sensitivity analyses were deemed not to be useful
because of the low number of trials and included children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
48 to 72 hours
We pooled data from two trials for this outcome (71 randomised
children, 41 (58%) included in analysis) (Hay 2009; Little 2013).
At 48 to 72 hours, the proportion of childrenwith pain did not sig-
nificantly differ between those treated with ibuprofen and parac-
etamol versus paracetamol alone (42% versus 53%, RR 0.71, 95%
CI 0.42 to 1.20, I² statistic = 0%, fixed-effect model) (Analysis
4.2). Subgroup and sensitivity analyses were deemed not to be
useful because of the low number of trials and included children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
4 to 7 days
We pooled data from two trials for this outcome (71 randomised
children, 41 (58%) included in analysis) were combined (Hay
2009; Little 2013). At four to seven days, the proportion of chil-
dren with pain did not significantly differ between those treated
with ibuprofen and paracetamol versus paracetamol alone (33%
versus 18%, RR 1.65, 95% CI 0.58 to 4.72, I² statistic = 0%,
fixed-effect model) (Analysis 4.3). Subgroup and sensitivity anal-
yses were deemed not useful because of the low number of trials
and included children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
2. Adverse events likely to be related to the use NSAIDs
(ibuprofen) and paracetamol or paracetamol alone
We included data from one trial (56 randomised children, 56
(100%) included in analysis) (Little 2013). No adverse events were
reported in this trial (Analysis 4.4).
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to low quality due to study limitations and
imprecise effect estimate (very small sample size and infrequent
occurrence of the outcome).
Secondary outcomes
1. Proportion of children with at most mild pain at various
time points
24 hours
We pooled data from two trials for this outcome (71 randomised
children, 41 (58%) included in analysis) (Hay 2009; Little 2013).
At 24 hours, the proportion of children with at most mild pain did
not significantly differ between those treated with ibuprofen and
paracetamol versus paracetamol alone (4% versus 18%). Data did
not enable pooling of the trial results; the summary statistic relates
only to Little 2013 (RR 0.21, 95%CI 0.02 to 1.74) (Analysis 4.5).
Subgroup and sensitivity analyses were deemed not to be useful
because of the low number of trials and included children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
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48 to 72 hours
We pooled data from two trials for this outcome (71 randomised
children, 41 (58%) included in analysis) (Hay 2009; Little 2013).
At 48 to 72 hours, the proportion of children with at most mild
pain did not significantly differ between those treated with ibupro-
fen and paracetamol versus paracetamol alone (21% versus 29%).
Data did not enable pooling of trial results; the summary statis-
tic relates only to Little 2013 (RR 0.63, 95% CI 0.24 to 1.62)
(Analysis 4.6). Subgroup and sensitivity analyses were deemed not
to be useful because of the low number of trials and included chil-
dren.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
4 to 7 days
We pooled data from two trials for this outcome (71 randomised
children, 41 (58%) included in analysis) (Hay 2009; Little 2013).
At four to seven days, the proportion of children with at most
mild pain did not significantly differ between those treated with
ibuprofen and paracetamol versus paracetamol alone (17% versus
29%). Data did not enable pooling of trial results; the summary
statistic relates only to Little 2013 (RR 0.50, 95%CI 0.17 to 1.43)
(Analysis 4.7). Subgroup and sensitivity analyses were deemed not
to be useful because of the low number of trials and included
children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
2. Mean time to resolution of pain
None of the included trials reported on this pre-specified sec-
ondary outcome.
3. Mean pain score at various time points
24 hours
We pooled data from two trials for this outcome (71 randomised
children, 40 (56%) included in analysis) (Hay 2009; Little 2013).
No differences were observed in mean pain scores at 24 hours be-
tween children treated with treated with ibuprofen and paraceta-
mol versus paracetamol alone (MD 0.32, 95%CI -0.59 to 1.23; I²
statistic = 61%, random-effects model) (Analysis 4.8). Subgroup
and sensitivity analyses were deemed not to be useful because of
the low number of trials and included children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
48 to 72 hours
We pooled data from two trials for this outcome (71 randomised
children, 40 (56%) included in analysis) (Hay 2009; Little 2013).
Nodifferences were observed inmean pain scores at 48 to 72 hours
between children treated with ibuprofen and paracetamol versus
paracetamol alone. Data did not enable pooling of trial results; the
summary statistic relates only to Little 2013 (MD 0.60, 95% CI
-0.77 to 1.97) (Analysis 4.9). Subgroup and sensitivity analyses
were deemed not to be useful because of the low number of trials
and included children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
4 to 7 days
We pooled data from two trials for this outcome (71 randomised
children, 33 (46%) included in analysis) (Hay 2009; Little 2013).
No differences were observed in mean pain scores at four to seven
days children treatedwith ibuprofen andparacetamol versus parac-
etamol alone. Data did not enable pooling of trial results; the sum-
mary statistic relates only to Little 2013 (MD 0.70, 95% CI -1.01
to 2.41) (Analysis 4.10). Subgroup and sensitivity analyses were
deemed not to be useful because of the low number of trials and
included children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
4. Disease-specific quality of life as measured by a validated
instrument
None of the included trials reported on this pre-specified sec-
ondary outcome.
5. Mean time to resolution of fever
None of the included trials reported on this pre-specified sec-
ondary outcome.
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6. Proportion of children with fever at various time points
24 hours
We pooled data from two trials for this outcome (71 randomised
children, 41 (58%) included in analysis) (Hay 2009; Little 2013).
Nodifferencewas observed in the proportionof childrenwith fever
at 24 hours between those treated with ibuprofen and paracetamol
versus paracetamol alone (50% versus 29%, RR 1.48, 95% CI
0.73 to 2.99; I² statistic = 0%, fixed-effect model) (Analysis 4.11).
Subgroup and sensitivity analyses were deemed not to be useful
because of the low number of trials and included children.
Quality of evidence
The evidence for this outcome was of very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
48 to 72 hours
We pooled data from two trials for this outcome (71 randomised
children, 41 (58%) included in analysis) (Hay 2009; Little 2013).
Nodifferencewas observed in the proportionof childrenwith fever
at 48 to 72 hours between those treated with ibuprofen and parac-
etamol versus paracetamol alone (29% versus 12%, RR 2.13, 95%
CI 0.60 to 7.60; I² statistic = 4%, fixed-effect model) (Analysis
4.12). Subgroup and sensitivity analyses were deemed not to be
useful because of the low number of trials.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
4 to 7 days
We pooled data from two trials for this outcome (71 randomised
children, 41 (58%) included in analysis) (Hay 2009; Little 2013).
None of the participants in either group had fever at four to
seven days (Analysis 4.13). Subgroup and sensitivity analyses were
deemed not to be useful because of the low number of trials and
included children.
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
7. Proportion of children with re-consultations
We included data from one trial (56 randomised children, 56
(100%) included in analysis) (Little 2013). No difference was
observed in the proportion of childrenwith re-consultations at day
28 between those treated with ibuprofen and paracetamol versus
paracetamol alone (66% versus 81%, RR 0.80, 95% CI 0.58 to
1.11) (Analysis 4.14).
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
8. Proportion of children with (delayed) antibiotic
prescriptions
We included data from one trial (56 randomised children, 56
(100%) included in analysis) (Little 2013). No difference was ob-
served in the proportion of children with delayed antibiotics be-
tween those treated with ibuprofen and paracetamol versus parac-
etamol alone (52% versus 41%, RR 1.27, 95% CI 0.71 to 2.26)
(Analysis 4.15).
Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (very small sample size).
9. Total days lost from nursery or school for children
because of AOM
None of the included trials reported on this pre-specified sec-
ondary outcome.
10. Total days lost from work or education for parents and
carers because of their child’s AOM
None of the included trials reported on this pre-specified sec-
ondary outcome.
11. Serious complications
We pooled data from two trials for this outcome (71 randomised
children, 71 (100%) included in analysis) (Hay 2009; Little 2013).
No serious complications related to AOM were reported in either
of the trials (Analysis 4.16). Subgroup and sensitivity analyses were
deemed not to be useful because of the low number of trials and
included children.
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Quality of evidence
The evidence for this outcome was very low quality; we down-
graded it from high to very low quality due to study limitations
and imprecise effect estimate (small sample size and infrequent
occurrence of the outcome).
A D D I T I O N A L S U M M A R Y O F F I N D I N G S [Explanation]
NSAIDs versus placebo for acute otitis media in children
Patients: children with acute ot it is media
Setting: outpat ients in four centres
Intervention: ibuprofen
Control: placebo
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with placebo Risk with ibuprofen
Pain at various time
points
24 hours no data available n/ a n/ a n/ a
48 to 72 hours (48 hours) Study populat ion RR 0.28
(0.11 to 0.70)
146
(1 RCT)
⊕⊕©©
low¹
NNTB based on the
study populat ion risk
was 1/ (253 to 71)* 1000
= 6
253 per 1000 71 per 1000
(28 to 177)
4 to 7 days no data available n/ a n/ a n/ a
Adverse events Study populat ion RR 1.76
(0.44 to 7.10)
146
(1 RCT)
⊕©©©
very low²
40 per 1000 70 per 1000
(18 to 284)
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M ean time to resolu-
tion of pain
no data available n/ a n/ a n/ a
M ean pain score at var-
ious time points
no data available n/ a n/ a n/ a
Fever at various time
points
24 hours no data available n/ a n/ a n/ a
48 to 72 hours (48 hours) Study populat ion RR 1.06
(0.07 to 16.57)
146
(1 RCT)
⊕©©©
very low³
13 per 1000 14 per 1000
(1 to 221)
4 to 7 days no data available n/ a n/ a n/ a
Re-consultations no data available n/ a n/ a n/ a
Delayed antibiotic pre-
scriptions
no data available n/ a n/ a n/ a
* The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
CI: Conf idence interval; NNTB: number needed to treat to benef it ; RR: Risk rat io; RCT: randomised controlled trial;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
¹ We downgraded the evidence f rom high to low quality due to study lim itat ions and quest ions about the applicability of
evidence.
² We downgraded the evidence f rom high to very low quality due to study lim itat ions and imprecise ef fect est imate (small
sample size and inf requent occurrence of the outcome).
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³ We downgraded the evidence f rom high to very low quality due to study lim itat ions, imprecise ef fect est imate (inf requent
occurrence of the outcome) and quest ions about the applicability of evidence.
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NSAIDs versus paracetamol for acute otitis media in children
Patients: children with acute ot it is media
Setting: community, primary care, secondary care
Intervention: ibuprofen
Control: paracetamol
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Quality of the evidence
(GRADE)
Comments
Risk with paracetamol Risk with ibuprofen
Pain at various time
points
24 hours Study populat ion RR 0.83
(0.59 to 1.18)
39
(2 RCTs)
⊕©©©
very low¹
778 per 1000 646 per 1000
(459 to 918)
48 to 72 hours Study populat ion RR 0.91
(0.54 to 1.54)
183
(3 RCTs)
⊕⊕©©
low²
178 per 1000 162 per 1000
(96 to 274)
4 to 7 days Study populat ion RR 0.74
(0.17 to 3.23)
38
(2 RCTs)
⊕©©©
very low¹
188 per 1000 139 per 1000
(32 to 606)
Adverse events Study populat ion RR 1.71
(0.43 to 6.90)
197
(2 RCTs)
⊕©©©
very low³
30 per 1000 51 per 1000
(13 to 207)
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M ean time to resolu-
tion of pain
no data available n/ a n/ a n/ a
M ean pain score at var-
ious time points* *
24 hours The mean pain score
with ibuprofen ranged
f rom 2.5 to 3.9
The mean pain score
with paracetamol was
on average 0.10 lower
(0.67 lower to 0.47
higher)
n/ a 39
(2 RCTs)
⊕©©©
very low¹
48 to 72 hours The mean pain score
with ibuprofen ranged
f rom 1.6 to 2.4
The mean pain score
with paracetamol was
on average 0.19 lower
(0.65 lower to 0.27
higher)
n/ a 39
(2 RCTs)
⊕©©©
very low¹
4 to 7 days The mean pain score
with ibuprofen ranged
f rom 1 to 2.2
The mean pain score
with paracetamol was
on average 0.30 higher
(1.78 lower to 2.38
higher)
n/ a 31
(2 RCTs)
⊕©©©
very low¹
Fever at various time
points
24 hours Study populat ion RR 0.69
(0.24 to 2.00)
39
(2 RCTs)
⊕©©©
very low¹
294 per 1000 203 per 1000
(71 to 588)
48 to 72 hours Study populat ion RR 1.18
(0.31 to 4.44)
182
(3 RCTs)
⊕⊕©©
low²
33 per 1000 39 per 1000
(10 to 148)
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4 to 7 days Study populat ion RR 2.75
(0.12 to 60.70)
39
(2 RCTs)
⊕©©©
very low¹
0 per 1000 0 per 1000
(0 to 0)
Re-consultations Study populat ion RR 1.13
(0.92 to 1.40)
53
(1 RCT)
⊕©©©
very low¹
815 per 1000 921 per 1000
(750 to 1.000)
Delayed antibiotic pre-
scriptions
Study populat ion RR 1.32
(0.74 to 2.35)
53
(1 RCT)
⊕©©©
very low¹
407 per 1000 538 per 1000
(301 to 957)
* The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95% CI).
* * Hay 2009 assessed fever-associated discomfort using a validated comfort scale (no comfort ; not quite normal; some pain/ distress; crying/ very distressed), whereas Lit t le
2013 assessed ear pain using a validated symptom score (ranging f rom 0 to 6 with 0 = no problem and 6 = as bad as it could be)
CI: Conf idence interval; NNTB: number needed to treat to benef it ; RR: Risk rat io; RCT: randomised controlled trial;
GRADE Working Group grades of evidence
High quality: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
M oderate quality: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low quality: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
¹ We downgraded the evidence high to very low quality due to study lim itat ions and imprecise ef fect est imate (very small
sample size).
² We downgraded the evidence f rom high to low quality due to study lim itat ions and quest ions about the applicability of
evidence.
³ We downgraded the evidence f rom high to very low quality due to study lim itat ions and imprecise ef fect est imate (small
sample size and inf requent occurrence of the outcome).
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D I S C U S S I O N
Summary of main results
Current evidence on the effectiveness of paracetamol or NSAIDs,
alone or combined, in relieving pain in children with AOM is
limited.
We included three RCTs (327 children) with low to moderate risk
of bias. One RCT compared paracetamol versus ibuprofen versus
placebo in 219 children with AOM. In this trial, children received
concurrent antibiotic therapy and those with fever > 39 °C could
have received paracetamol (30 mg to 60 mg) in addition to the
studied treatments. Authors of two RCTs comparing paracetamol
versus ibuprofen versus paracetamol and ibuprofen in children
with fever and patients with respiratory tract infections provided
crude subgroup data on children with AOM (26 and 82 children,
respectively).
We found low quality evidence, derived from one trial, that both
paracetamol and ibuprofen as monotherapies were more effec-
tive than placebo in relieving pain at 48 hours (paracetamol ver-
sus placebo: proportion of children with pain 10% versus 25%,
NNTB 7; ibuprofen versus placebo: proportion of children with
pain 7% versus 25%, NNTB 6).
Adverse events did not significantly differ between children treated
with either paracetamol, ibuprofen or placebo. However, this find-
ing should be interpreted with caution because it occurred infre-
quently and limited numbers of participants’ data were available
for analysis.
We found insufficient evidence of a difference between ibuprofen
and paracetamol in relieving short-term ear pain.
We could not draw any firm conclusions on the effectiveness of
ibuprofen plus paracetamol versus paracetamol alone in relieving
ear pain in children with AOMmainly because of the very limited
participants’ data available for analysis.
Overall completeness and applicability of
evidence
We included one trial comparing the effectiveness of paracetamol,
ibuprofen and placebo in children with AOM as diagnosed by
otoscopy (Bertin 1996). All trial participants, however, received
co-treatment with antibiotics (cefaclor 15 to 30 mg/kg twice daily
for 7 days) which is no longer routinely recommended for use in
themanagement of children with AOM. Although oral antibiotics
have onlymarginal beneficial effect in relieving ear pain in children
with AOM (Venekamp 2015), co-treatment with antibiotics may
potentially have influenced the trial findings.
For the other included trials (Hay 2009; Little 2013), we included
subgroup data from children with fever and patients with respi-
ratory tract infections. In these trials, AOM was diagnosed either
by the GP or research nurse without further specification of diag-
nostic criteria applied.
Furthermore, the dosage of paracetamol used in the double-blind
randomised trial comparing paracetamol versus ibuprofen versus
placebo was relatively low (10 mg/kg 3 times daily) (Bertin 1996).
This may have underestimated the effect of paracetamol in this
trial. In the same trial (Bertin 1996), children with fever > 39
°C could be given paracetamol (30 mg to 60 mg) in addition to
the studied treatments which may have substantially influenced
trial findings. As such, the overall degree of completeness and
applicability of evidence is low.
Quality of the evidence
The quality of the evidence for primary outcomes looking at ef-
fectiveness in the trial comparing paracetamol versus placebo and
ibuprofen versus placebo was low, whereas the quality of evidence
for adverse events and secondary effectiveness outcomes was very
low.
The quality of the evidence for primary outcomes looking at ef-
fectiveness in the trials comparing ibuprofen versus paracetamol
varied from low to very low quality, whereas the quality of evi-
dence for adverse events and secondary effectiveness outcomes was
mostly very low.
The quality of evidence for all outcomes in the trials comparing
ibuprofen plus paracetamol versus paracetamol alone was very low.
Potential biases in the review process
We used a broad search strategy (not only including otitis media
but also upper respiratory tract infection as search terms) without
language or publication restrictions. For feasibility purposes we
did not include fever in our search strategy, but we systematically
screened reference lists of all relevant reviews on the effectiveness
of paracetamol and/or NSAIDs for children with fever including
relevant Cochrane reviews (Meremikwu 2005; Wong 2013). Af-
ter screening reference lists of these reviews, we found three po-
tentially relevant trials that were not retrieved from our database
searches (Hay 2009; Sarrell 2006; McIntyre 1996). We therefore
feel confident that our review includes all relevant trials.
We were unable to retrieve AOM subgroup data from one po-
tentially relevant trial (Sarrell 2006). However, it is unlikely these
subgroup data would have a major impact on our review findings.
Agreements and disagreements with other
studies or reviews
No previous review has been undertaken to assess the effectiveness
of paracetamol or NSAIDs, alone or combined, in children with
AOM. Previous Cochrane reviews on paracetamol or NSAIDs (or
both) focused either on children with fever due to infectious dis-
eases (Meremikwu 2005; Wong 2013), or included both children
and adults with the common cold (Kim 2013). For children with
30Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in
children (Review)
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fever, the reviews found only few trials comparing paracetamol
against placebo (Meremikwu 2005), some evidence that both al-
ternating and combined antipyretic therapy may be more effective
at reducing temperatures than monotherapy alone and inconclu-
sive evidence for measures of child discomfort (Wong 2013). For
the common cold, the review concluded that “NSAIDs are some-
what effective in relieving discomfort caused by a cold but there is
no clear evidence of their effect in easing respiratory symptoms”
(Kim 2013).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Current evidence on the effectiveness of paracetamol or NSAIDs,
alone or combined, in relieving pain in children with AOM is
limited.
Data fromone trial indicated that both paracetamol and ibuprofen
as monotherapies were more effective than placebo in relieving
ear pain at 48 hours in children with AOM. However, quality of
evidence was judged as low due to study limitations and questions
about the applicability of evidence.
Low to very low quality evidence suggested no difference between
ibuprofen and paracetamol in relieving short-term ear pain in chil-
dren with AOM. However, these findings should be interpreted
very carefully since study limitations, very small sample size and
questions about applicability of evidence, substantially affected
our confidence in the results.
Current available evidence on the effectiveness of ibuprofen plus
paracetamol versus paracetamol alone is insufficient to draw any
firm conclusions.
Implications for research
Despite explicit guideline recommendations on the use of anal-
gesics in children with AOM (Lieberthal 2013), analgesics are
infrequently recommended to parents of children with AOM in
daily practice (Pulkki 2006).Moreover, semi structured interviews
with Australian parents of children who had recently visited their
GP with AOM revealed that parents considered analgesics insuffi-
cient as stand-alone treatment (Hansen 2015). Increasing parental
knowledge and physicians’ adherence to guidelines on the use of
analgesics in childhood AOM seems warranted since suboptimal
management of ear pain may lead to unnecessary discomfort of
the child, sleepless nights, and days off work for parents, and pre-
ventable doctor re-consultations because of persistingAOMsymp-
toms. RCTs assessing the effectiveness of interventions aimed at
both physicians and parents involved in the care of children with
AOMare needed to evaluate whether optimised painmanagement
(paracetamol at fixed time intervals in an appropriate dose instead
of as required, and ibuprofen as rescue medication) provides any
benefit over care as usual in relieving AOM symptoms and reduc-
ing re-consultations and (delayed) antibiotic prescriptions.
Further RCTs are also needed to assess the effectiveness of ibupro-
fen as adjunct to paracetamol versus paracetamol alone and to es-
tablish whether other analgesics such as anaesthetic eardrops are
beneficial in relieving ear pain in children with AOM.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bertin 1996
Methods Allocation: randomised
Design: 3-arm, parallel group, double-blind design
Participants Number: 219 children (219 included in analysis)
Age: 1 year to 6.75 years
Gender: 96 female (44%), 123 male (56%)
Setting: children seen as outpatients in four centres
Inclusion criteria: the diagnosis of AOM was based on the aspect of the tympanic
membrane using a semi-quantitative scale (“tympanic score”) from 0 to 6. The tympanic
score had to be ≥ 3 for at least one ear for patients to be eligible
Exclusion criteria: cardiac; hepatic or renal disorders; gastroduodenal disease; known
hypersensitivity to NSAIDs and penicillins or receiving either antibiotic; analgesic; di-
uretic or anti-inflammatory drugs within one week before the study. Patients with AOM
requiring myringotomy, or with chronic otitis were not eligible
Interventions Intervention group 1:NSAIDs (ibuprofen) 10 mg/kg orally, 3 times daily, for 48 hours.
N = 71
Intervention group 2: PCM 10 mg/kg orally, 3 times daily, for 48 hours. N = 73
Comparator group: placebo orally, 3 times daily, for 48 hours. N = 75
Use of additional interventions: All children received antibiotics: Cefaclor 15-30 mg/
kg orally, two times daily, for 7 days. In case of fever > 39 °C, children could be given
acetaminophen (30 mg to 60 mg/kg/day) additionally to the studied treatment. In case
of fever ≥ 39 °C external cooling techniques (e.g. sponging) were allowed
Outcomes Primary outcome: aspect of the tympanic membrane, as described with the tympanic
score
Secondary outcomes: ear pain, rectal temperature, quality of life (based on appetite,
sleep and playing activity), tolerance
Outcome assessment:
Evaluation of ear pain: dichotomous (0 = no pain; pain in the ear = 1)
Fever (rectal temperature): 0 = < 37° C, 1 = 37.1° C to 38.4° C, and 2 = > 38.5° C
Tolerance: presence or absence of nausea, vomiting, abdominal pain and cutaneous rash
Funding sources All treatments were supplied by Ethypharm
Declaration of interest No information provided
Notes Participants lost to follow-up total: according to tables, no children were lost to follow-
up
Paracetamol has been prescribed 10 mg/kg, three times daily. Nowadays this would be
considered as a suboptimal dosage
Risk of bias Risk of bias
35Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in
children (Review)
Copyright © 2016 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Bertin 1996 (Continued)
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Patients were randomised using a com-
puter-generated list
Allocation concealment (selection bias) Unclear risk Method not described
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quote: “Participants were given ibuprofen
microgranules (in packets of 100 or 200
mg), or identically looking acetaminophen
and placebo microgranules.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Double-blind; Subjective outcomes rele-
vant for this review were assessed by par-
ents/children. Blinding of participants was
adequate
Incomplete outcome data (attrition bias)
All outcomes
Low risk Loss to follow-up has not been explicitly
described.However, following information
provided in the tables, no childrenwere lost
to follow-up
Selective reporting (reporting bias) Unclear risk Noprotocol available; insufficient informa-
tion to permit a judgement of low or high
risk. Both positive and negative outcomes,
however, have been reported in the paper
Other bias Unclear risk Baseline characteristics: balanced
All children were included in analysis; un-
clear whether ITT analysis was performed
Formal sample size calculations were per-
formed
Compliance of treatment: no information
provided
Hay 2009
Methods Allocation: randomised
Design: three-arm, parallel group, double-blind design
Participants Number: 156 children, 26 children diagnosed with AOM
Age: between 0.5 to 6 years
Gender: 68 female (44%), 88 male (56%)
Setting: community, primary care (including out-of-hours services) and secondary care
(emergency department of a children’s hospital)
Inclusion criteria: children aged between 6 months and 6 years with fever ≥ 37.8° C
and ≤ 41° C due to an illness that could be managed at home
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Hay 2009 (Continued)
Exclusion criteria: previous participation in the PITCH trial or in another drug trial in
the previous 30 days; weight 7 kg or less; illness requiring hospital admission; epilepsy
or other chronic neurological disease; allergy or intolerance to the study medication;
known study medicine contraindication; skin conditions precluding the use of adhesive
tape; peptic ulceration or bleeding; known diagnosis or any ongoing investigating into
suspected cardiac disease pulmonary disease, liver disease, kidney disease; and parents/
legal guardians who could not read or write English
Interventions Intervention group 1: NSAIDs (ibuprofen) 10 mg/kg orally, repeated every 6-8 hours
(max 3 doses in 24 hours), for 48 hours. N = 11/52 diagnosed with AOM
Intervention group 2: PCM 15 mg/kg orally repeated every 4 to 6 hours (max 4 doses
in 24 hours), for 48 hours. N = 7/52 diagnosed with AOM
Comparator group: PCM + NSAIDs combined. Ibuprofen 10 mg/kg orally, repeated
every 6 to 8 hours, and PCM 15 mg/kg orally repeated every 4 to 6 hours, for 48 hours.
N = 8/52 diagnosed with AOM
Use of additional interventions: All children received a standardised advice sheet re-
garding fever in children, with the advice to: 1) use the study medicine as instructed;
2) keep the child lightly dressed in a room with normal temperature; and 3) give cool
drinks
Outcomes Primary outcomes: time without fever within the first four hours and the proportion
of children scoring no fever-associated discomfort at 48 hours
Secondary outcomes: time until first fever clearance, time without fever within the first
24 hours, activity, appetite, sleep, adverse effects and costs (including lost days of work
for parents and daycare/school for children)
Outcome assessment:
Time without fever: number of minutes in the first 24 hours using a continuous axillary
thermometer. Temperature was also assessed using an axillary digital thermometer at 4,
16, 24, 48 hours at day 5
Fever-associated discomfort at 48 hours: validated comfort scale (no comfort; not quite
normal; some pain/distress; crying/very distressed) completed by parents in a symptom
diary at 0, 2, 4, 16, 24, 32, 40 and 48 hours and day 5
Time until first fever clearance: time in minutes until the temperature first fell below the
fever threshold of 37.2° C using a continuous axillary thermometer
Adverse effects: measured at 24 hours, 48 hours and at day 5
Lost days of work for parents and daycare/school for children: a research nurse visited
the child at baseline, 24-hours, 48-hours and performed a telephone call at day 5
The number of children treated with antibiotics were recorded
The number of return visits were recorded as part of the economic evaluation
Funding sources The study was funded by the NIHR HTA programme. The active drugs and matched
placeboswere purchased fromandprovided byPfizer andDHPInvestigationalMedicinal
Products
Declaration of interest Quote: “The views and opinions expressed in the paper did not necessarily reflect those of
theNIHRHTA,NCCRCD, orDepartment of Health.” Pfizer andDHP Investigational
Medicinal Products had no role in the design, conduct, analysis, or reporting of the trial
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Hay 2009 (Continued)
Notes Participants lost to follow-up total: 3/156 (2%) for time without fever within the first
four hours and 0/156 for fever-associated discomfort at 48 hours
Participants lost to follow-up NSAID group: 1/52 (2%). No reasons were provided
Participants lost to follow-up PCM group: 0/52 children
Participants lost to follow-up NSAID + PCM group: 2/52 children (4%). No reasons
were provided
The diagnose AOM was made by the GP. No further details were provided on the
diagnostic criteria
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotes: “The randomisation sequence was
generated via a remote, automated tele-
phone service provided by the Health Ser-
vices Research Unit at the University of
Aberdeen.” “Eligible children were ran-
domised with a block size of six and strat-
ified according to five minimisation vari-
ables, ...”
Allocation concealment (selection bias) Low risk Quote: “The study medicines were pro-
vided by Pfizer Ltd and sent to DHP Ltd,
a manufacturer of clinical trials medicines.
DHP was aware of the randomisation pro-
cedure and the company was asked to sup-
ply the study medicines to the trial fully
concealed.”
Blinding of participants and personnel
(performance bias)
All outcomes
Low risk Quotes: “Study medicines were provided
in a white cardboard pack containing the
two bottles, one of paracetamol/placebo
and one of ibuprofen/placebo suspensions.
The identity of the next treatment alloca-
tion was concealed from research nurses by
the fact that they carried at least one un-
opened box of six medicine packs during
any randomisation visit.” “After inputting
participant information required for ran-
domisation, the research nurses were in-
formed which pack to give to the child.”
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk Quote: “The parents, principal investi-
gator, trial co-ordinator, research nurses
and project administrator were all blinded
to the study medicines allocated to ran-
domised children throughout the recruit-
ment and analysis periods.”
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Hay 2009 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Low risk For discomfort there was no lost to follow-
up, whereas 3 children (2%) were lost to
follow-up for time without fever
Selective reporting (reporting bias) Low risk All outcomes have been described accord-
ing to the protocol
Other bias Low risk Baseline characteristics: balanced
ITT analysis performed
Formal sample size calculations were per-
formed.However they did not achieve their
original sample size (831 children)
Compliance of treatment: Quote: “First, in
the first 24 hours, parents administered the
minimum intended doses of paracetamol
or placebo (four doses) to 42% to 65% of
children and of ibuprofen or placebo (three
doses) to 71% to 75% of children. This
suggests that three times daily dosing is su-
perior or more likely to be adhered to than
four times daily dosing and may have con-
tributed towards greater ibuprofen efficacy.
”
Little 2013
Methods Allocation: randomised
Design: parallel, open 3 x 2 x 2 factorial trial
Participants Number: 889 participants, 82 diagnosed with AOM
Age: three years and older
Gender: 540 female (61%), 349 male (39%)
Setting: patients presented to a GP or nurse in primary care (in total 53 GPs and practice
nurses in 25 practices)
Inclusion criteria: patients aged three years and older presenting to a GP or nurse in
primary care with a respiratory tract infection diagnosed by the health professional
Exclusion criteria: asthma (unless it was not sensitive to ibuprofen or aspirin); peptic
ulcer; hypersensitivity to analgesics; inability to complete outcomes; conditions requiring
hospital admission; immunodeficiency; pregnancy; and breastfeeding
Interventions Intervention group 1: NSAIDs (ibuprofen). N = 26/290 diagnosed with AOM
Intervention group 2: PCM. N = 27/302 diagnosed with AOM
Comparator group: PCM + NSAIDs (ibuprofen) alternating. N = 29/254 diagnosed
with AOM
The dose of paracetamol and ibuprofen used in this trial were the maximum recom-
mended by the British National Formulary (which varies by age)
Use of additional interventions: Patients were not only randomised to the three drug
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Little 2013 (Continued)
groups, but also to two dosing groups and two steam groups. The dosing advice groups
were to use drugs regularly four times for at least three days or to take drugs as required.
The steam advice was to inhale with steam for at least 15 minutes (five minutes three
times a day) or no steam inhalation
Outcomes Primary outcome: symptom control
Secondary outcomes: side effects (rash, diarrhoea, vomiting, abdominal pain), temper-
ature, antibiotic use, return visits
Outcome assessment:
Symptom control: mean symptom severity at the end of each day, averaged over days
two to four of a two week symptom diary using a format for rating symptoms (0 = no
problem, 6 = as bad as it could be)
Side effects: such as vomiting, diarrhoea, rash or abdominal pain, reported in a two week
symptom diary
Temperature: mean morning and evening temperature reading with Tempadot ther-
mometers (orally where possible) averaged over days two to four
Antibiotic use: documented in the diary. Randomisation was stratified by antibiotic
prescription strategy (immediate versus delayed)
Return visit: a return with a symptom or diagnosis of respiratory tract infection recorded
with a structured pro forma by a member of the research team. Complications were
defined as a new consultation documented in the notes within 28 days
Funding sources The study was funded by the National Institute for Health Research Programme Grants
for Applied Research programme
Declaration of interest All authors declared none
Notes Participants lost to follow-up total: 138/889 (16%) for symptom severity
Participants lost to follow-up NSAID group: 43/297 (15%)
Participants lost to follow-up PCM group: 51/305 children (17%)
Participants lost to follow-up NSAID + PCM group: 49/287 (15%)
The diagnose AOM was made by the GP or research nurse. No further details were
provided on the diagnostic criteria
There was no advice regarding the dose of paracetamol and ibuprofen
Risk of bias Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Quotes: “A statistician independent of the
study team coordinated the randomisation,
..” “Patients were randomised to one of 12
advice groups”...“, with computer gener-
ated random number tables to determine
one of 12 advice slips contained in sealed
numbered envelopes.”
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Little 2013 (Continued)
Allocation concealment (selection bias) Low risk Quote: “..the clinician took the next pack
off the shelf that contained pre-randomised
advice sheets”. As described above the ad-
vice slips were contained in sealed num-
bered envelopes
Blinding of participants and personnel
(performance bias)
All outcomes
High risk Not blinded
Blinding of outcome assessment (detection
bias)
All outcomes
High risk Not blinded
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk 138/889 (16%) for symptom severity;
Quote: “The characteristics of patients in
whom the primary outcome was not doc-
umented were similar to those followed up
...”
Selective reporting (reporting bias) Low risk All outcomes have been described accord-
ing to the protocol
Other bias Low risk Baseline characteristics: balanced
ITT analysis with complete data (no impu-
tation of missing data)
Formal sample size calculations were per-
formed
Compliance of treatment: Quote: “From
themaindiary data for paracetamol use, pa-
tients took amean of 4.2 doses a day for the
first three days in the paracetamol group,
3.5 in the combined group, and 0.4 in the
ibuprofen group. For ibuprofen, patients
took amean of 0.3 doses in the paracetamol
group, 2.9 in the ibuprofen group, and 2.7
in the combined group. Steam inhalation
was reported a mean of 1.6 times a day in
the steam group for days two and three and
0.1 times in the no steam group. Advice to
use analgesic regularly compared with as re-
quired made little difference to the amount
of analgesia used for either paracetamol (2.
8 doses v 2.4 doses) or ibuprofen (2.0 doses
v 1.9 doses).”
AOM: acute otitis media
GP: general practitioner
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NSAID: non-steroidal anti-inflammatory drug
PCM: paracetamol
ITT: intention-to-treat
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Azuma 2010 PARTICIPANTS
Adults only (no children included)
Campos 1992 ALLOCATION
Non-randomised study
Cappella 1993 INTERVENTIONS
Trial comparing nimesulide (NSAID) versus lysine-acetyl salicylate
Caretti 1986 PARTICIPANTS
Study did not include children with AOM (only tonsillitis and pharyngitis)
Dasgupta 2002 INTERVENTIONS
Trial comparing nizer (NSAID) versus nimesulide (NSAID)
Eccles 2006 PARTICIPANTS
Adults only (no children included)
Fort 2000 INTERVENTIONS
Trial comparing ibuprofen (NSAID) versus Lysine clonixinate (NSAID)
Gonzales 1989 PARTICIPANTS
Study did not include children with AOM (only tonsillitis, pharyngitis, tracheitis, bronchitis and pneumonia)
Kim CK 2013 INTERVENTIONS
Trial comparing dexibuprofen (NSAID) 3.5 or 7 mg/kg versus ibuprofen 5 or 10 mg/kg (NSAID)
McIntyre 1996 PARTICIPANTS
Trial included hospitalised children
Metta 2000 INTERVENTIONS
Trial comparing ibuprofen (NSAID) versus Lysine clonixinate (NSAID)
Milvio 1984 INTERVENTIONS
Trial comparing nimesulide (NSAID) versus benzydamine (NSAID)
Motoichi 1997 PARTICIPANTS
Adults only (no children included)
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Nouri 1984 PARTICIPANTS
Adults only (no children included)
Passali 2001 INTERVENTIONS
Trial comparing nimesulide (\NSAID) versus morniflumate (NSAID)
Polidori 1993 PARTICIPANTS
Trial included both outpatient and hospitalised children
Ryan 1987 PARTICIPANTS
Adults only (no children included)
Sarrell 2006 OTHER
We did not succeed to receive the crude subgroup data of children with AOM from this trial
Schuetz 2014 ALLOCATION
Non-randomised study
Siegel 2003 ALLOCATION
Non-randomised study
Siquet 1983 INTERVENTIONS
Trial comparing fentiazac (NSAID) versus ibuprofen (NSAID)
Stipon 1983 INTERVENTIONS
Trial comparing an intravenous injection of UP 341.01 (bio-precursor of paracetamol) 1 gram versus 2 gram
Weippl 1985 INTERVENTIONS
Trial comparing suprofen (NSAID) versus lidocaine + phenazone ear drops
Yoon 2008 INTERVENTIONS
Trial comparing dexibuprofen (NSAID) 5 or 7 mg/kg versus 10 mg ibuprofen (NSAID)
Characteristics of ongoing studies [ordered by study ID]
PIM-POM study 2014
Trial name or title Pain Intensity Monitoring in Paediatric Otitis Media (PIM-POM) study
Methods Cluster randomised controlled trial
Participants Children aged 6 months to 10 years presenting to their general practitioner (GP) with ear pain resulting in a
GP diagnosis of AOM according to the diagnostic criteria of the practice guideline “AOM in children” issued
by the Dutch College of GPs
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PIM-POM study 2014 (Continued)
Interventions Intervention group: a primary-care based multifaceted intervention: 1) a blended learning targeted at general
practitioners (GPs) consisting of an Internet-based training combined with a face-to-face visit with the study
physician; 2) an interactive parent information leaflet; and 3) a prescription of paracetamol and ibuprofen to
be filled by parents the same day. In the blended learning GPs will be trained to a) address pain management
during consultation by using effective communication skills; b) adhere to the 2014 guideline “AOM in
children” and the 2007 “Pain Relief ’ guideline issued by the Dutch College of GPs which recommend a high
dose paracetamol at fixed time intervals for the first three days, and a non-steroidal anti-inflammatory drug
(NSAID) as add-on if needed; c) use an interactive leaflet during consultation; and d) prescribe paracetamol
and ibuprofen (as add-on if needed)
Comparator group: ‘care as usual’
Outcomes Primary outcome:mean ear pain score during the first 3 days after the initial visit to the GP as measured by
the Wong-Baker FACES® Pain Rating Scale (WBS)
Secondary outcomes: number of days with ear pain and ear pain severity; number of days with fever;
proportion of children with ear pain at various time points (24 hours, 2 to 3 days, 4 to 7 days); GP re-
consultations because of AOM; (delayed) antibiotic prescriptions because of AOM; health-related quality of
life (HRQoL) of the child and its parents; parental days off work, days lost from nursery or school for children;
complications of AOM, including acute mastoiditis, meningitis and intracranial abscess; adverse effects of
analgesics; costs (cost-effectiveness)
Starting date January 2015
Contact information Prof.dr. Roger AMJ Damoiseaux
Notes Alies Sjoukes, Roderick P Venekamp, Alma C van de Pol, Anne GM Schilder, Roger AMJ Damoiseaux are
researchers of the PIM-POMstudy;This trial is fundedby a research grant fromTheNetherlandsOrganisation
for Health Research and Development/SBOH no. 80-83910-98-13006
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D A T A A N D A N A L Y S E S
Comparison 1. Paracetamol versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain at 48 hours 1 148 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.17, 0.85]
2 Adverse events 1 148 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.21, 4.93]
3 Fever at 48 hours 1 148 Risk Ratio (M-H, Fixed, 95% CI) 1.03 [0.07, 16.12]
Comparison 2. NSAIDs versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain at 48 hours 1 146 Risk Ratio (M-H, Fixed, 95% CI) 0.28 [0.11, 0.70]
2 Adverse events 1 146 Risk Ratio (M-H, Fixed, 95% CI) 1.76 [0.44, 7.10]
3 Fever at 48 hours 1 146 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.07, 16.57]
Comparison 3. NSAIDs versus paracetamol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain at 24 hours 2 39 Risk Ratio (M-H, Fixed, 95% CI) 0.83 [0.59, 1.18]
2 Pain at 48 to 72 hours 3 183 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.54, 1.54]
3 Pain at 4 to 7 days 2 38 Risk Ratio (M-H, Fixed, 95% CI) 0.74 [0.17, 3.23]
4 Adverse events 2 197 Risk Ratio (M-H, Random, 95% CI) 1.71 [0.43, 6.90]
5 Mild pain at 24 hours 2 39 Risk Ratio (M-H, Fixed, 95% CI) 1.08 [0.31, 3.73]
6 Mild pain at 48 to 72 hours 2 39 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.62, 2.91]
7 Mild pain at 4 to 7 days 2 39 Risk Ratio (M-H, Fixed, 95% CI) 0.91 [0.37, 2.23]
8 Mean pain score at 24 hours 2 39 Mean Difference (IV, Fixed, 95% CI) 0.10 [-0.47, 0.67]
9 Mean pain score at 48 to 72
hours
2 39 Mean Difference (IV, Fixed, 95% CI) 0.19 [-0.27, 0.65]
10 Mean pain score at 4 to 7 days 2 31 Mean Difference (IV, Fixed, 95% CI) -0.30 [-2.38, 1.78]
11 Fever at 24 hours 2 39 Risk Ratio (M-H, Fixed, 95% CI) 0.69 [0.24, 2.00]
12 Fever at 48 to 72 hours 3 182 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.31, 4.44]
13 Fever at 4 to 7 days 2 39 Risk Ratio (M-H, Fixed, 95% CI) 2.75 [0.12, 60.70]
14 Re-consultations 1 53 Risk Ratio (M-H, Fixed, 95% CI) 1.13 [0.92, 1.40]
15 Delayed antibiotic prescriptions 1 53 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [0.74, 2.35]
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Comparison 4. NSAIDs + paracetamol versus paracetamol
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain at 24 hours 2 41 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.78, 1.47]
2 Pain at 48 to 72 hours 2 41 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.42, 1.20]
3 Pain at 4 to 7 days 2 41 Risk Ratio (M-H, Fixed, 95% CI) 1.65 [0.58, 4.72]
4 Adverse events 1 56 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
5 Mild pain at 24 hours 2 41 Risk Ratio (M-H, Fixed, 95% CI) 0.21 [0.02, 1.74]
6 Mild pain at 48 to 72 hours 2 41 Risk Ratio (M-H, Fixed, 95% CI) 0.63 [0.24, 1.62]
7 Mild pain at 4 to 7 days 2 41 Risk Ratio (M-H, Fixed, 95% CI) 0.5 [0.17, 1.43]
8 Mean pain at 24 hours 2 40 Mean Difference (IV, Random, 95% CI) 0.32 [-0.59, 1.23]
9 Mean pain at 48 to 72 hours 2 40 Mean Difference (IV, Fixed, 95% CI) 0.60 [-0.77, 1.97]
10 Mean pain at 4 to 7 days 2 33 Mean Difference (IV, Fixed, 95% CI) 0.7 [-1.01, 2.41]
11 Fever at 24 hours 2 41 Risk Ratio (M-H, Fixed, 95% CI) 1.48 [0.73, 2.99]
12 Fever at 48 to 72 hours 2 41 Risk Ratio (M-H, Fixed, 95% CI) 2.13 [0.60, 7.60]
13 Fever at 4 to 7 days 2 41 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
14 Re-consultations 1 56 Risk Ratio (M-H, Fixed, 95% CI) 0.80 [0.58, 1.11]
15 Delayed antibiotic prescriptions 1 56 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.71, 2.26]
16 Serious complications 2 71 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
Analysis 1.1. Comparison 1 Paracetamol versus placebo, Outcome 1 Pain at 48 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 1 Paracetamol versus placebo
Outcome: 1 Pain at 48 hours
Study or subgroup Paracetamol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bertin 1996 7/73 19/75 100.0 % 0.38 [ 0.17, 0.85 ]
Total (95% CI) 73 75 100.0 % 0.38 [ 0.17, 0.85 ]
Total events: 7 (Paracetamol), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.37 (P = 0.018)
Test for subgroup differences: Not applicable
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Favours paracetamol Favours placebo
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Analysis 1.2. Comparison 1 Paracetamol versus placebo, Outcome 2 Adverse events.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 1 Paracetamol versus placebo
Outcome: 2 Adverse events
Study or subgroup Paracetamol Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bertin 1996 3/73 3/75 100.0 % 1.03 [ 0.21, 4.93 ]
Total (95% CI) 73 75 100.0 % 1.03 [ 0.21, 4.93 ]
Total events: 3 (Paracetamol), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.03 (P = 0.97)
Test for subgroup differences: Not applicable
0.1 0.2 0.5 1 2 5 10
Favours paracetamol Favours placebo
Analysis 1.3. Comparison 1 Paracetamol versus placebo, Outcome 3 Fever at 48 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 1 Paracetamol versus placebo
Outcome: 3 Fever at 48 hours
Study or subgroup Paracetamol Control Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bertin 1996 1/73 1/75 100.0 % 1.03 [ 0.07, 16.12 ]
Total (95% CI) 73 75 100.0 % 1.03 [ 0.07, 16.12 ]
Total events: 1 (Paracetamol), 1 (Control)
Heterogeneity: not applicable
Test for overall effect: Z = 0.02 (P = 0.98)
Test for subgroup differences: Not applicable
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Analysis 2.1. Comparison 2 NSAIDs versus placebo, Outcome 1 Pain at 48 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 2 NSAIDs versus placebo
Outcome: 1 Pain at 48 hours
Study or subgroup Ibuprofen Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bertin 1996 5/71 19/75 100.0 % 0.28 [ 0.11, 0.70 ]
Total (95% CI) 71 75 100.0 % 0.28 [ 0.11, 0.70 ]
Total events: 5 (Ibuprofen), 19 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 2.70 (P = 0.0070)
Test for subgroup differences: Not applicable
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Analysis 2.2. Comparison 2 NSAIDs versus placebo, Outcome 2 Adverse events.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 2 NSAIDs versus placebo
Outcome: 2 Adverse events
Study or subgroup Ibuprofen Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bertin 1996 5/71 3/75 100.0 % 1.76 [ 0.44, 7.10 ]
Total (95% CI) 71 75 100.0 % 1.76 [ 0.44, 7.10 ]
Total events: 5 (Ibuprofen), 3 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 2.3. Comparison 2 NSAIDs versus placebo, Outcome 3 Fever at 48 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 2 NSAIDs versus placebo
Outcome: 3 Fever at 48 hours
Study or subgroup Ibuprofen Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bertin 1996 1/71 1/75 100.0 % 1.06 [ 0.07, 16.57 ]
Total (95% CI) 71 75 100.0 % 1.06 [ 0.07, 16.57 ]
Total events: 1 (Ibuprofen), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.04 (P = 0.97)
Test for subgroup differences: Not applicable
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Analysis 3.1. Comparison 3 NSAIDs versus paracetamol, Outcome 1 Pain at 24 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 1 Pain at 24 hours
Study or subgroup Ibuprofen Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 3/11 3/7 25.0 % 0.64 [ 0.18, 2.31 ]
Little 2013 9/10 11/11 75.0 % 0.90 [ 0.69, 1.17 ]
Total (95% CI) 21 18 100.0 % 0.83 [ 0.59, 1.18 ]
Total events: 12 (Ibuprofen), 14 (Paracetamol)
Heterogeneity: Chi2 = 0.49, df = 1 (P = 0.48); I2 =0.0%
Test for overall effect: Z = 1.02 (P = 0.31)
Test for subgroup differences: Not applicable
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Analysis 3.2. Comparison 3 NSAIDs versus paracetamol, Outcome 2 Pain at 48 to 72 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 2 Pain at 48 to 72 hours
Study or subgroup Ibuprofen Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bertin 1996 5/71 7/73 41.8 % 0.73 [ 0.24, 2.21 ]
Hay 2009 3/11 1/7 7.4 % 1.91 [ 0.24, 14.91 ]
Little 2013 8/11 8/10 50.8 % 0.91 [ 0.56, 1.46 ]
Total (95% CI) 93 90 100.0 % 0.91 [ 0.54, 1.54 ]
Total events: 16 (Ibuprofen), 16 (Paracetamol)
Heterogeneity: Chi2 = 0.65, df = 2 (P = 0.72); I2 =0.0%
Test for overall effect: Z = 0.35 (P = 0.73)
Test for subgroup differences: Not applicable
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Analysis 3.3. Comparison 3 NSAIDs versus paracetamol, Outcome 3 Pain at 4 to 7 days.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 3 Pain at 4 to 7 days
Study or subgroup Ibuprofen Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 2/11 0/6 16.7 % 2.92 [ 0.16, 52.47 ]
Little 2013 1/11 3/10 83.3 % 0.30 [ 0.04, 2.46 ]
Total (95% CI) 22 16 100.0 % 0.74 [ 0.17, 3.23 ]
Total events: 3 (Ibuprofen), 3 (Paracetamol)
Heterogeneity: Chi2 = 1.56, df = 1 (P = 0.21); I2 =36%
Test for overall effect: Z = 0.40 (P = 0.69)
Test for subgroup differences: Not applicable
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Analysis 3.4. Comparison 3 NSAIDs versus paracetamol, Outcome 4 Adverse events.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 4 Adverse events
Study or subgroup Ibuprofen Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N
M-
H,Random,95%
CI
M-
H,Random,95%
CI
Bertin 1996 5/71 3/73 100.0 % 1.71 [ 0.43, 6.90 ]
Little 2013 0/26 0/27 Not estimable
Total (95% CI) 97 100 100.0 % 1.71 [ 0.43, 6.90 ]
Total events: 5 (Ibuprofen), 3 (Paracetamol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 3.5. Comparison 3 NSAIDs versus paracetamol, Outcome 5 Mild pain at 24 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 5 Mild pain at 24 hours
Study or subgroup Ibuprofen Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 1/11 0/7 16.0 % 2.00 [ 0.09, 43.22 ]
Little 2013 3/11 3/10 84.0 % 0.91 [ 0.24, 3.51 ]
Total (95% CI) 22 17 100.0 % 1.08 [ 0.31, 3.73 ]
Total events: 4 (Ibuprofen), 3 (Paracetamol)
Heterogeneity: Chi2 = 0.22, df = 1 (P = 0.64); I2 =0.0%
Test for overall effect: Z = 0.13 (P = 0.90)
Test for subgroup differences: Not applicable
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Analysis 3.6. Comparison 3 NSAIDs versus paracetamol, Outcome 6 Mild pain at 48 to 72 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 6 Mild pain at 48 to 72 hours
Study or subgroup Ibuprofen Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 1/11 0/7 10.3 % 2.00 [ 0.09, 43.22 ]
Little 2013 7/11 5/10 89.7 % 1.27 [ 0.59, 2.73 ]
Total (95% CI) 22 17 100.0 % 1.35 [ 0.62, 2.91 ]
Total events: 8 (Ibuprofen), 5 (Paracetamol)
Heterogeneity: Chi2 = 0.08, df = 1 (P = 0.77); I2 =0.0%
Test for overall effect: Z = 0.76 (P = 0.45)
Test for subgroup differences: Not applicable
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Analysis 3.7. Comparison 3 NSAIDs versus paracetamol, Outcome 7 Mild pain at 4 to 7 days.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 7 Mild pain at 4 to 7 days
Study or subgroup Ibuprofen Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 0/11 0/7 Not estimable
Little 2013 5/11 5/10 100.0 % 0.91 [ 0.37, 2.23 ]
Total (95% CI) 22 17 100.0 % 0.91 [ 0.37, 2.23 ]
Total events: 5 (Ibuprofen), 5 (Paracetamol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.21 (P = 0.83)
Test for subgroup differences: Not applicable
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Analysis 3.8. Comparison 3 NSAIDs versus paracetamol, Outcome 8 Mean pain score at 24 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 8 Mean pain score at 24 hours
Study or subgroup Ibuprofen Paracetamol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hay 2009 11 2.45 (0.93) 7 2.43 (0.53) 72.0 % 0.02 [ -0.66, 0.70 ]
Little 2013 11 3.9 (1.1) 10 3.6 (1.4) 28.0 % 0.30 [ -0.78, 1.38 ]
Total (95% CI) 22 17 100.0 % 0.10 [ -0.47, 0.67 ]
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.34 (P = 0.74)
Test for subgroup differences: Not applicable
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Analysis 3.9. Comparison 3 NSAIDs versus paracetamol, Outcome 9 Mean pain score at 48 to 72 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 9 Mean pain score at 48 to 72 hours
Study or subgroup Ibuprofen Paracetamol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hay 2009 11 2.36 (0.67) 7 2.14 (0.38) 89.4 % 0.22 [ -0.27, 0.71 ]
Little 2013 11 1.6 (1.8) 10 1.7 (1.5) 10.6 % -0.10 [ -1.51, 1.31 ]
Total (95% CI) 22 17 100.0 % 0.19 [ -0.27, 0.65 ]
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 0.79 (P = 0.43)
Test for subgroup differences: Not applicable
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Analysis 3.10. Comparison 3 NSAIDs versus paracetamol, Outcome 10 Mean pain score at 4 to 7 days.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 10 Mean pain score at 4 to 7 days
Study or subgroup Ibuprofen Paracetamol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hay 2009 11 2.18 (0.4) 7 2 (0) Not estimable
Little 2013 6 1 (2) 7 1.3 (1.8) 100.0 % -0.30 [ -2.38, 1.78 ]
Total (95% CI) 17 14 100.0 % -0.30 [ -2.38, 1.78 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.28 (P = 0.78)
Test for subgroup differences: Not applicable
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Analysis 3.11. Comparison 3 NSAIDs versus paracetamol, Outcome 11 Fever at 24 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 11 Fever at 24 hours
Study or subgroup Ibuprofen Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 1/11 0/7 10.3 % 2.00 [ 0.09, 43.22 ]
Little 2013 3/11 5/10 89.7 % 0.55 [ 0.17, 1.72 ]
Total (95% CI) 22 17 100.0 % 0.69 [ 0.24, 2.00 ]
Total events: 4 (Ibuprofen), 5 (Paracetamol)
Heterogeneity: Chi2 = 0.63, df = 1 (P = 0.43); I2 =0.0%
Test for overall effect: Z = 0.67 (P = 0.50)
Test for subgroup differences: Not applicable
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Analysis 3.12. Comparison 3 NSAIDs versus paracetamol, Outcome 12 Fever at 48 to 72 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 12 Fever at 48 to 72 hours
Study or subgroup Ibuprofen Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Bertin 1996 1/71 1/73 27.5 % 1.03 [ 0.07, 16.12 ]
Hay 2009 1/11 0/7 16.7 % 2.00 [ 0.09, 43.22 ]
Little 2013 2/10 2/10 55.8 % 1.00 [ 0.17, 5.77 ]
Total (95% CI) 92 90 100.0 % 1.18 [ 0.31, 4.44 ]
Total events: 4 (Ibuprofen), 3 (Paracetamol)
Heterogeneity: Chi2 = 0.16, df = 2 (P = 0.92); I2 =0.0%
Test for overall effect: Z = 0.24 (P = 0.81)
Test for subgroup differences: Not applicable
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Analysis 3.13. Comparison 3 NSAIDs versus paracetamol, Outcome 13 Fever at 4 to 7 days.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 13 Fever at 4 to 7 days
Study or subgroup Ibuprofen Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 0/11 0/7 Not estimable
Little 2013 1/11 0/10 100.0 % 2.75 [ 0.12, 60.70 ]
Total (95% CI) 22 17 100.0 % 2.75 [ 0.12, 60.70 ]
Total events: 1 (Ibuprofen), 0 (Paracetamol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.64 (P = 0.52)
Test for subgroup differences: Not applicable
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Analysis 3.14. Comparison 3 NSAIDs versus paracetamol, Outcome 14 Re-consultations.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 14 Re-consultations
Study or subgroup Ibuprofen Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Little 2013 24/26 22/27 100.0 % 1.13 [ 0.92, 1.40 ]
Total (95% CI) 26 27 100.0 % 1.13 [ 0.92, 1.40 ]
Total events: 24 (Ibuprofen), 22 (Paracetamol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.16 (P = 0.25)
Test for subgroup differences: Not applicable
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Analysis 3.15. Comparison 3 NSAIDs versus paracetamol, Outcome 15 Delayed antibiotic prescriptions.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 3 NSAIDs versus paracetamol
Outcome: 15 Delayed antibiotic prescriptions
Study or subgroup Ibuprofen Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Little 2013 14/26 11/27 100.0 % 1.32 [ 0.74, 2.35 ]
Total (95% CI) 26 27 100.0 % 1.32 [ 0.74, 2.35 ]
Total events: 14 (Ibuprofen), 11 (Paracetamol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.95 (P = 0.34)
Test for subgroup differences: Not applicable
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Analysis 4.1. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 1 Pain at 24 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 1 Pain at 24 hours
Study or subgroup NSAIDs and PCM Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 3/8 3/7 21.7 % 0.88 [ 0.25, 3.02 ]
Little 2013 16/16 9/10 78.3 % 1.12 [ 0.88, 1.44 ]
Total (95% CI) 24 17 100.0 % 1.07 [ 0.78, 1.47 ]
Total events: 19 (NSAIDs and PCM), 12 (Paracetamol)
Heterogeneity: Chi2 = 0.25, df = 1 (P = 0.62); I2 =0.0%
Test for overall effect: Z = 0.42 (P = 0.67)
Test for subgroup differences: Not applicable
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Analysis 4.2. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 2 Pain at 48 to 72 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 2 Pain at 48 to 72 hours
Study or subgroup NSAIDs and PCM Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 0/8 1/7 13.9 % 0.30 [ 0.01, 6.29 ]
Little 2013 10/16 8/10 86.1 % 0.78 [ 0.48, 1.28 ]
Total (95% CI) 24 17 100.0 % 0.71 [ 0.42, 1.20 ]
Total events: 10 (NSAIDs and PCM), 9 (Paracetamol)
Heterogeneity: Chi2 = 0.45, df = 1 (P = 0.50); I2 =0.0%
Test for overall effect: Z = 1.27 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 4.3. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 3 Pain at 4 to 7 days.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 3 Pain at 4 to 7 days
Study or subgroup NSAIDs and PCM Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 2/8 0/7 12.5 % 4.44 [ 0.25, 79.42 ]
Little 2013 6/16 3/10 87.5 % 1.25 [ 0.40, 3.90 ]
Total (95% CI) 24 17 100.0 % 1.65 [ 0.58, 4.72 ]
Total events: 8 (NSAIDs and PCM), 3 (Paracetamol)
Heterogeneity: Chi2 = 0.68, df = 1 (P = 0.41); I2 =0.0%
Test for overall effect: Z = 0.94 (P = 0.35)
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
Favours NSAIDs and PCM Favours paracetamol
Analysis 4.4. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 4 Adverse events.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 4 Adverse events
Study or subgroup NSAIDs and PCM Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Little 2013 0/29 0/27 Not estimable
Total (95% CI) 29 27 Not estimable
Total events: 0 (NSAIDs and PCM), 0 (Paracetamol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.5. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 5 Mild pain at 24 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 5 Mild pain at 24 hours
Study or subgroup NSAIDs and PCM Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 0/8 0/7 Not estimable
Little 2013 1/16 3/10 100.0 % 0.21 [ 0.02, 1.74 ]
Total (95% CI) 24 17 100.0 % 0.21 [ 0.02, 1.74 ]
Total events: 1 (NSAIDs and PCM), 3 (Paracetamol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.45 (P = 0.15)
Test for subgroup differences: Not applicable
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Analysis 4.6. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 6 Mild pain at 48 to 72
hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 6 Mild pain at 48 to 72 hours
Study or subgroup NSAIDs and PCM Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 0/8 0/7 Not estimable
Little 2013 5/16 5/10 100.0 % 0.63 [ 0.24, 1.62 ]
Total (95% CI) 24 17 100.0 % 0.63 [ 0.24, 1.62 ]
Total events: 5 (NSAIDs and PCM), 5 (Paracetamol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.96 (P = 0.33)
Test for subgroup differences: Not applicable
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Analysis 4.7. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 7 Mild pain at 4 to 7 days.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 7 Mild pain at 4 to 7 days
Study or subgroup NSAIDs and PCM Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 0/8 0/7 Not estimable
Little 2013 4/16 5/10 100.0 % 0.50 [ 0.17, 1.43 ]
Total (95% CI) 24 17 100.0 % 0.50 [ 0.17, 1.43 ]
Total events: 4 (NSAIDs and PCM), 5 (Paracetamol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.29 (P = 0.20)
Test for subgroup differences: Not applicable
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Analysis 4.8. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 8 Mean pain at 24 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 8 Mean pain at 24 hours
Study or subgroup NSAIDs and PCM Paracetamol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Hay 2009 8 2.38 (0.52) 7 2.43 (0.53) 61.2 % -0.05 [ -0.58, 0.48 ]
Little 2013 15 4.5 (1.1) 10 3.6 (1.4) 38.8 % 0.90 [ -0.13, 1.93 ]
Total (95% CI) 23 17 100.0 % 0.32 [ -0.59, 1.23 ]
Heterogeneity: Tau2 = 0.28; Chi2 = 2.57, df = 1 (P = 0.11); I2 =61%
Test for overall effect: Z = 0.69 (P = 0.49)
Test for subgroup differences: Not applicable
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Analysis 4.9. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 9 Mean pain at 48 to 72
hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 9 Mean pain at 48 to 72 hours
Study or subgroup NSAIDs and PCM Paracetamol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hay 2009 8 2 (0) 7 2.14 (0.38) Not estimable
Little 2013 15 2.3 (2) 10 1.7 (1.5) 100.0 % 0.60 [ -0.77, 1.97 ]
Total (95% CI) 23 17 100.0 % 0.60 [ -0.77, 1.97 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.86 (P = 0.39)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
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Analysis 4.10. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 10 Mean pain at 4 to 7
days.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 10 Mean pain at 4 to 7 days
Study or subgroup NSAIDs and PCM Paracetamol
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Hay 2009 8 2.25 (0.46) 7 2 (0) Not estimable
Little 2013 11 2 (1.8) 7 1.3 (1.8) 100.0 % 0.70 [ -1.01, 2.41 ]
Total (95% CI) 19 14 100.0 % 0.70 [ -1.01, 2.41 ]
Heterogeneity: not applicable
Test for overall effect: Z = 0.80 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 4.11. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 11 Fever at 24 hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 11 Fever at 24 hours
Study or subgroup NSAIDs and PCM Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 1/8 0/7 7.9 % 2.67 [ 0.13, 56.63 ]
Little 2013 11/16 5/10 92.1 % 1.38 [ 0.68, 2.78 ]
Total (95% CI) 24 17 100.0 % 1.48 [ 0.73, 2.99 ]
Total events: 12 (NSAIDs and PCM), 5 (Paracetamol)
Heterogeneity: Chi2 = 0.18, df = 1 (P = 0.67); I2 =0.0%
Test for overall effect: Z = 1.09 (P = 0.28)
Test for subgroup differences: Not applicable
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Analysis 4.12. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 12 Fever at 48 to 72
hours.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 12 Fever at 48 to 72 hours
Study or subgroup NSAIDs and PCM Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 3/8 0/7 17.7 % 6.22 [ 0.38, 102.93 ]
Little 2013 4/16 2/10 82.3 % 1.25 [ 0.28, 5.61 ]
Total (95% CI) 24 17 100.0 % 2.13 [ 0.60, 7.60 ]
Total events: 7 (NSAIDs and PCM), 2 (Paracetamol)
Heterogeneity: Chi2 = 1.04, df = 1 (P = 0.31); I2 =4%
Test for overall effect: Z = 1.17 (P = 0.24)
Test for subgroup differences: Not applicable
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Analysis 4.13. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 13 Fever at 4 to 7 days.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 13 Fever at 4 to 7 days
Study or subgroup NSAIDs and PCM Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 0/8 0/7 Not estimable
Little 2013 0/16 0/10 Not estimable
Total (95% CI) 24 17 Not estimable
Total events: 0 (NSAIDs and PCM), 0 (Paracetamol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
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Analysis 4.14. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 14 Re-consultations.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 14 Re-consultations
Study or subgroup NSAIDs and PCM Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Little 2013 19/29 22/27 100.0 % 0.80 [ 0.58, 1.11 ]
Total (95% CI) 29 27 100.0 % 0.80 [ 0.58, 1.11 ]
Total events: 19 (NSAIDs and PCM), 22 (Paracetamol)
Heterogeneity: not applicable
Test for overall effect: Z = 1.34 (P = 0.18)
Test for subgroup differences: Not applicable
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Analysis 4.15. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 15 Delayed antibiotic
prescriptions.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 15 Delayed antibiotic prescriptions
Study or subgroup NSAID and PCM Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Little 2013 15/29 11/27 100.0 % 1.27 [ 0.71, 2.26 ]
Total (95% CI) 29 27 100.0 % 1.27 [ 0.71, 2.26 ]
Total events: 15 (NSAID and PCM), 11 (Paracetamol)
Heterogeneity: not applicable
Test for overall effect: Z = 0.81 (P = 0.42)
Test for subgroup differences: Not applicable
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Analysis 4.16. Comparison 4 NSAIDs + paracetamol versus paracetamol, Outcome 16 Serious
complications.
Review: Paracetamol (acetaminophen) or non-steroidal anti-inflammatory drugs, alone or combined, for pain relief in acute otitis media in children
Comparison: 4 NSAIDs + paracetamol versus paracetamol
Outcome: 16 Serious complications
Study or subgroup NSAID and PCM Paracetamol Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Hay 2009 0/8 0/7 Not estimable
Little 2013 0/29 0/27 Not estimable
Total (95% CI) 37 34 Not estimable
Total events: 0 (NSAID and PCM), 0 (Paracetamol)
Heterogeneity: not applicable
Test for overall effect: not applicable
Test for subgroup differences: Not applicable
0.01 0.1 1 10 100
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A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 [mh “otitis media”] OR otitis media OR aom OR ome OR (middle AND ear AND (effusion OR inflammation* OR infection*))
OR glue ear
#2 [mh “respiratory tract infection”] OR respiratory infection* OR (acute OR upper) respiratory AND (symptom* OR illness* OR
infection* OR inflammation*)
#3 #1 OR #2
#4 [mh acetaminophen] OR paracetamol OR acetaminophen OR acetaminophen OR tylenol OR [mh “Anti-Inflammatory Agents,
Non-Steroidal”] OR (nonsteroidal OR ’non steroidal’ AND (antiinflammatory OR ’anti inflammatory’)) OR nsaid OR nsaids
#5 [mh pain] OR [mh “Pain Management”] OR Pain OR Pains OR Ache OR Aches OR analgesia
#6 #3 AND #4 AND #5
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Appendix 2. MEDLINE (Ovid) search strategy
1 exp Otitis Media/ OR otitis media OR aom OR ome OR (middle ear adj2 (effusion OR inflam* OR infection OR infections)) OR
glue ear
2 exp Respiratory Tract Infections/ OR (respiratory adj2 infection*) OR ((acute or upper) adj2 respiratory adj2 (symptom* or illness*
or infect* or inflam*))
3 1 OR 2
4 exp Acetaminophen/ OR paracetamol OR acetaminophen OR acetaminophen OR tylenol OR exp Anti-Inflammatory Agents, Non-
Steroidal/ OR ((nonsteroid* or non-steroid*) adj1 (antiinflam* or anti-inflam*)) OR nsaid or nsaids
5 exp Pain/ OR exp Pain Management/ OR Pain OR Pains OR Ache OR Aches OR Analgesia
6 ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or randomised.ab. or placebo.ab. or drug therapy.fs.
or randomly.ab. or trial.ab. or groups.ab.) not (exp animals/ not humans.sh.)
7 3 AND 4 AND 5 AND 6
Appendix 3. Embase search strategy
#1 ’otitis media’/exp OR otitis media OR aom OR ome OR (middle AND ear AND (effusion OR inflammation* OR infection*))
OR glue ear
#2 ’respiratory tract infection’/exp OR respiratory infection* OR (acute OR upper) respiratory AND (symptom* OR illness* OR
infection* OR inflammation*)
#3 #1 OR #2
#4 ’paracetamol’/exp OR paracetamol OR acetaminophen OR acetaminophen OR tylenol OR ’nonsteroid antiinflammatory agent’/
exp OR (nonsteroidal OR ’non steroidal’ AND (antiinflammatory OR ’anti inflammatory’)) OR nsaid OR nsaids
#5 ’pain’/exp OR ’analgesia’/exp OR Pain OR Pains OR Ache OR Aches OR analgesia
#6 random* OR factorial OR crossover OR placebo OR blind OR blinded OR assign OR assigned OR allocate OR allocated OR
’crossover procedure’/exp OR ’double-blind procedure’/exp OR ’randomized controlled trial’/exp OR ’single-blind procedure’/exp
#7 #3 AND #4 AND #5 AND #6
Appendix 4. CINAHL search strategy
S1 (MH “Otitis Media+”) OR otitis media OR aom OR ome OR (middle ear (effusion OR inflammation* OR infection*)) OR glue
ear
S2 (MH “Respiratory Tract Infections+”) OR respiratory infection* OR (acute OR upper) respiratory (symptom* OR illness* OR
infection* OR inflammation*)
S3 S1 OR S2
S4 (MH “Acetaminophen”) OR paracetamol OR acetaminophen OR acetaminophen OR tylenol OR (MH “Antiinflammatory Agents,
Non-Steroidal+”) OR (nonsteroid* OR non-steroid*) (antiinflam* or anti-inflam*) OR nsaid OR nsaids
S5 (MH “Pain+”) OR (MH “Analgesia+”) OR Pain OR Pains OR Ache OR Aches OR Analgesia
S6 (MH “Clinical Trials+”) OR random* OR factorial OR crossover OR placebo OR blind OR blinded OR assign OR assigned OR
allocate OR allocated OR trial OR trials OR groups
S7 S3 AND S4 AND S5 AND S6
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Appendix 5. LILACS search strategy
(tw:(Otitis media OR aom OR ome OR (middle ear (effusion OR inflammation* OR infection*)) OR glue ear OR Respiratory
infection* OR (acute OR upper) respiratory (symptom* OR illness* OR infection* OR inflammation*)))
AND
(tw:(Paracetamol OR acetaminophen OR acetaminophen OR tylenol OR (nonsteroid* OR non-steroid*) (antiinflam* or anti-inflam*)
OR nsaid OR nsaids))
AND
(tw:(Pain OR Pains OR Ache OR Aches OR Analgesia))
AND
(tw:(random* OR factorial OR crossover OR placebo OR blind OR blinded OR assign OR assigned OR allocate OR allocated OR
trial OR trials OR groups))
Appendix 6. Web of Science search strategy
#1 TOPIC: (Otitis media OR aom OR ome OR (middle ear (effusion OR inflammation* OR infection*)) OR glue ear) OR TOPIC:
(Respiratory infection* OR (acute OR upper) respiratory (symptom* OR illness* OR infection* OR inflammation*))
#2 TOPIC: (Paracetamol OR acetaminophen OR acetaminophen OR tylenol OR (nonsteroid* OR non-steroid*) (antiinflam* or
anti-inflam*) OR nsaid OR nsaids) AND TOPIC: (Pain OR Pains OR Ache OR Aches OR Analgesia) AND TOPIC: (random* OR
factorial OR crossover OR placebo OR blind OR blinded OR assign OR assigned OR allocate OR allocated OR trial OR trials OR
groups)
#3 #2 AND #1
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I N D E X T E R M S
Medical Subject Headings (MeSH)
Acetaminophen [∗therapeutic use]; Acute Disease; Analgesics, Non-Narcotic [∗therapeutic use]; Anti-Bacterial Agents [therapeutic use];
Anti-Inflammatory Agents, Non-Steroidal [therapeutic use]; Drug Therapy, Combination; Fever [drug therapy]; Ibuprofen [therapeutic
use]; Otitis Media [∗complications]; Pain [∗drug therapy; etiology]; Randomized Controlled Trials as Topic
MeSH check words
Child; Child, Preschool; Humans
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